Podcasts about attd

  • 15PODCASTS
  • 51EPISODES
  • 17mAVG DURATION
  • 1MONTHLY NEW EPISODE
  • Apr 23, 2025LATEST

POPULARITY

20172018201920202021202220232024


Best podcasts about attd

Latest podcast episodes about attd

The insuleoin Podcast - Redefining Diabetes
#255: Eoin's Recap Of His Trip To The ATTD Conference.

The insuleoin Podcast - Redefining Diabetes

Play Episode Listen Later Apr 23, 2025 24:09


Eoin sits down with Graham to chat about his recent trip with Medtronic to the ATTD conference in Amsterdam.ATTD stands for 'Advanced Technologies & Treatments for Diabetes' and Eoin discusses some of the things he took away from the conference including:His changing attitude towards pumps.Interesting exercises undertaken at the conference.Observations from a restaurant full of T1Ds.As always, be sure to rate, comment, subscribe and share. Your interaction and feedback really helps the podcast. The more Diabetics that we reach, the bigger impact we can make!Questions & Stories for the Podcast?:theinsuleoinpodcast@gmail.comConnect, Learn & Work with Eoin:https://linktr.ee/insuleoin Hosted on Acast. See acast.com/privacy for more information.

Diabetes Connections with Stacey Simms Type 1 Diabetes
In the News.. FDA warns Dexcom, Inreda dual-chambered pump, using insulin with GLP-1 meds studied, and more!

Diabetes Connections with Stacey Simms Type 1 Diabetes

Play Episode Listen Later Mar 28, 2025 8:20


It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Learning more about the FDA letter sent to Dexcom, news from ATTD including a bihormonal pump from a Dutch company, time in tight range update, more studies about using insulin and GLP-1 medications, eating chili to prevent gestational diabetes (really!) and more..  Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Our top story this week: Dexcom Dive Brief: A warning letter posted Tuesday by the Food and Drug Administration revealed quality control issues with Dexcom's continuous glucose monitors. The FDA raised concerns with a design change to a component used in the resistance layer of Dexcom's sensors. The sensors with the new component were less accurate than those with the original component, according to the warning letter. Dexcom has ceased distribution of G7 sensors with the component, but the company's response did not address affected G6 sensors. J.P. Morgan analyst Robbie Marcus wrote in a research note Tuesday that the letter concerns a chemical compound that the sensor wire is dipped in. Dexcom began producing the compound internally to add redundancy to its supply chain.   Dive Insight: Dexcom Chief Operating Officer Jake Leach said in an interview with MedTech Dive last week that the company does not expect the warning letter to affect future product approvals, including a 15-day version of its G7 CGM, and there's no need yet to recall products. Dexcom has submitted the device to the FDA and anticipates a launch in the second half of the year.   Marcus, after speaking to company leadership and a quality control expert, wrote that many of the issues outlined in the letter could be addressed quickly. He added that the warning letter could explain minor delays in approval to the 15-day sensor, but Dexcom is still within the 90-day window for a 510(k) submission.   “While there's always a risk this could impede future product approvals,” Marcus wrote, “we do not expect this to materially delay the 15 day G7 sensor approval.”   The warning letter followed an FDA inspection last year of Dexcom's facilities in San Diego and Mesa, Arizona. Marcus wrote that after the FDA requested additional information and a separate 510(k), Dexcom stopped in-sourcing the compound and reverted back to the external supplier.   Dexcom's devices were misbranded because the company did not submit a premarket notification to the FDA before making major changes to the sensors, according to the warning letter. The sensors with the changed coating “cause higher risks for users who rely on the sensors to dose insulin or make other diabetes treatment decisions,” the letter said.     The FDA raised other concerns in the warning letter, including procedures to monitor the glucose and acetaminophen concentrations used in testing of the G6 and G7 CGMs. The FDA also cited problems with Dexcom's handling last year of a deficiency in its G6 sensors with dissolved oxygen content values, a key input for measuring blood glucose levels. https://www.medtechdive.com/news/dexcom-warning-letter-cgm-coating-change/743597/ XX Lots of studies and info out of the recent ATTD conference. One highlight that has been sort of under the radar: a Dutch company has been using a Bihormonal fully closed-loop system for the treatment of type 1 diabetes in the real world. This is a company called Inreda (in-RAY-duh). The Inreda AP® is an automatic system (closed loop) and independently regulates the blood glucose level by administering insulin and glucagon. The AP5 is certified in Europe and is being used in multiple studies and projects. The AP®6 is currently under development. https://www.inredadiabetic.nl/en/discover-the-ap/ https://pubmed.ncbi.nlm.nih.gov/38443309/ XX Let's talk about time in tight range. If you follow me and diabetes connections on social, you likely saw a video I made about this – it blew up last week. If not.. time in range has been a metric for a short while now.. in 2019 there was a consensus report advising a goal of 70% of time in the 70-180 mg/dL range for most people with type 1 diabetes (T1D) and type 2 diabetes (T2D), with modifications for certain subgroups. Recently we've been hearing more about 70-140 mg/dL — for longer periods as “time in tight range (TiTR).” At ATTD there was more talk about calling that range TING, or “time in normal glycemia.     There's a great writeup that I'll link up from the great Miriam Tucker on Medscape about a debate that happened at ATTD. On March 22, 2025, two endocrinologists debated this question at the Advanced Technologies & Treatments for Diabetes (ATTD) 2025. Anders L. Carlson, MD, medical director of the International Diabetes Center (IDC), Minneapolis, took the positive side, while Jeremy Pettus, MD, assistant professor of medicine at the University of California San Diego, who lives with T1D himself, argued that it's too soon.   https://www.medscape.com/viewarticle/should-time-tight-range-be-primary-diabetes-goal-2025a100073q?form=fpf   XX Sequel Med Tech announces its twist pump will be firs paired with Abbott's FreeStyle Libre 3 Plus. The twist has FDA approval for ages 6 and up and is set to begin its commercial launch by the end of June. The pump—designed by inventor Dean Kamen's Deka Research & Development—also incorporates the FDA-cleared Tidepool Loop software program, to record CGM blood sugar readings, make predictions based on trends and adjust its background insulin levels accordingly. https://www.fiercebiotech.com/medtech/sequel-med-tech-connects-twiist-insulin-pump-abbotts-cgm-ahead-market-debut XX Dexcom's longer-lasting CGM sensor looks promising, based on study results presented at the conference. The trial showed that the new 15-day G7 system is slightly more accurate than the current G7. The accuracy of CGM can be measured using MARD (mean absolute relative difference), which shows the average amount a CGM sensor varies from your actual glucose levels (a lower number is better).  The 15-day G7 has a MARD value of 8.0%, about the same as the Abbott Freestyle Libre 3. The Dexcom G7 15 Day is awaiting FDA approval and is not yet available in the U.S.   XX Little bit of news from Modular Medical.. they plan to submit their patch pump to the FDA late summer or fall of this year. The MODD1 product, a 90-day patch pump, features new microfluidics technology to allow for the low-cost pumping of insulin. Its new intuitive design makes the product simple to use and easier to prescribe. It has a reservoir size of 300 units/3mL. Users can monitor the pump activity with their cell phone and do not require an external controller. The pump uses a provided, single-use, disposable battery. Modular Medical picked up FDA clearance for MODD1 in September. The company also raised $8 million to end 2024. Its founder, Paul DiPerna, previously founded leading insulin pump maker Tandem Diabetes Care. DiPerna invented and designed Tandem's t:slim pump. By developing its patented insulin delivery technologies, the company hopes to improve access to glycemic control. Its founder, Paul DiPerna, previously founded leading insulin pump maker Tandem Diabetes Care. DiPerna invented and designed Tandem's t:slim pump. https://www.drugdeliverybusiness.com/modular-medical-announces-12m-private-placement/ XX More from attd – type 2 news? https://www.drugdeliverybusiness.com/biggest-diabetes-tech-news-attd-2025/ XX Another study that says people with type 1 who use a GLP-1 medication get better outcomes. In this study, those who use GLP-1 with insulin are 55% less likely to have a hyperglycemia-related ED visit, 26% less likely to have an amputation-related visit, and 29% less likely to have a diabetic ketoacidosis (DKA)-related ED visit in the following year compared to those on insulin alone. Although they are not approved for T1D, some patients may receive them off-label or for weight control. Pretty big study for an off label drug: compared 7,010 adult patients with T1D who were prescribed GLP-1s and insulin to 304,422 adult patients with T1D who were on insulin alone.  It is important to note that the rates of new diabetic complications in one year for both groups were around 1%, indicating that these are uncommon outcomes regardless of medication use. https://www.epicresearch.org/articles/some-diabetic-complications-less-likely-among-type-1-diabetics-on-glp-1s   XX Early research here but exposure to antibiotics during a key developmental window in infancy may stunt the growth of insulin-producing cells in the pancreas and boost risk of diabetes later in life The study, is published this month in the journal Science, it's a study in mice. These researchers are working off the idea that when while identical twins share DNA that predisposes them to Type 1 diabetes, only one twin usually gets the disease. She explained that human babies are born with a small amount of pancreatic “beta cells,” the only cells in the body that produce insulin.   But some time in a baby's first year, a once-in-a-lifetime surge in beta cell growth occurs.   “If, for whatever reason, we don't undergo this event of expansion and proliferation, that can be a cause of diabetes,” Hill said.   They found that when they gave broad-spectrum antibiotics to mice during a specific window (the human equivalent of about 7 to 12 months of life), the mice developed fewer insulin producing cells, higher blood sugar levels, lower insulin levels and generally worse metabolic function in adulthood.   in other experiments, the scientists gave specific microbes to mice, and found that several they increased their production of beta cells and boosted insulin levels in the blood. When male mice that were genetically predisposed to Type 1 diabetes were colonized with the fungus in infancy, they developed diabetes less than 15% of the time. Males that didn't receive the fungus got diabetes 90% of the time. Even more promising, when researchers gave the fungus to adult mice whose insulin-producing cells had been killed off, those cells regenerated. Hill stresses that she is not “anti-antibiotics.” But she does imagine a day when doctors could give microbe-based drugs or supplements alongside antibiotics to replace the metabolism-supporting bugs they inadvertently kill.   .   “Historically we have interpreted germs as something we want to avoid, but we probably have way more beneficial microbes than pathogens,” she said. “By harnessing their power, we can do a lot to benefit human health.”     https://www.eurekalert.org/news-releases/1078112 XX Future watch for something called BeaGL - created by researchers at the University of California Davis and UC Davis Health who were inspired by their own personal experiences with managing T1D.   BeaGL is designed to work with CGMs and has security-focused machine learning algorithms to make predictive alerts about anticipated glucose changes, which are sent to a device. In this case, a smartwatch. The end goal is for BeaGL to be completely automated to reduce the cognitive load on the patient, particularly for teens. It's still in research phase but six student with T1D have been using it for almost a year.     https://health.ucdavis.edu/news/headlines/with-ai-a-new-metabolic-watchdog-takes-diabetes-care-from-burden-to-balance/2025/02 XX Investigators are searching for a way forward after two long-term diabetes programs were terminated following the cancellation of their National Institutes of Health (NIH) funding, the result of federal allegations that study coordinator Columbia University had inappropriately handled antisemitism on campus. The programs include the three-decades-old Diabetes Prevention Program (DPP) and its offshoot, the Diabetes Prevention Program Outcomes Study (DPPOS). “We are reeling,” said David Nathan, MD, a previous chair of both the DPP and the DPPOS and an original leader of the landmark Diabetes Control and Complications Trial. Nathan is also founder of the Massachusetts General Hospital Diabetes Center in Boston, one of the 30 DPPOS sites in 21 states. On March 7, the Trump administration cancelled $400 million in awards to Columbia University from various federal agencies. While Columbia University agreed on March 21 to changes in policies and procedures to respond to the Trump administration's charges, in the hopes that the funding would be restored, DPPOS Principal Investigator Jose Luchsinger, MD, told Medscape Medical News that as of press time, the study was still cancelled. https://www.medscape.com/viewarticle/diabetes-prevention-program-cancellation-colossal-waste-2025a100076h XX XX Type 2 diabetes may quietly alter the brain in ways that mimic early Alzheimer's. This was only an animal study – but researchers say the high comorbidity of type 2 diabetes (T2D) with psychiatric or neurodegenerative disorders points to a need for understanding what links these diseases.   https://scitechdaily.com/how-diabetes-quietly-rewires-the-brains-reward-and-memory-system/ XX Eating chili once a month when you're pregnant seems to lower the risk of developing gestational diabetes. This is a real study! While chili showed a link to lower gestational diabetes risk, dried beans and bean soup had no significant effect, even among women who ate them more frequently. Some studies suggest that diets high in beans and legumes, including the Mediterranean diet, reduce GDM risk. While studies link beans to lower diabetes risk, their specific impact on GDM remains unclear. This study analyzed data from 1,397 U.S. pregnant women who participated in the Infant Feeding Practices Study II, conducted between 2005 and 2007. Chili consumption varied significantly by race, education, household size, income, supplemental nutrition status, and region. Non-Hispanic Black mothers consumed the most (0.33 cups/week), while those with higher income and education levels consumed less. Regional differences also influenced chili intake. One possible mechanism for chili's effect is capsaicin, a bioactive compound found in chili peppers, which has been linked to metabolic benefits in other studies. However, further research is needed to confirm this potential role in GDM prevention. Dried bean and bean soup consumption had no clear association with GDM. The study highlights limitations due to self-reported dietary data and the need for more detailed dietary measures. https://www.news-medical.net/news/20250317/Could-a-little-spice-in-your-diet-prevent-gestational-diabetes.aspx XX

BSP Podcast
Different Styles Of Betting! Eagles Continue To Roll Vs Rams? Vegas Catching On To Jalen Hurt ATTD

BSP Podcast

Play Episode Listen Later Nov 22, 2024 18:26


Nick McClay from FoxtheGambler joins the show and helps Brendan dive into some new ways to look at sports betting #nfl #subscribe #gambling Go Subscribe to @coldoneconversations7867 Use Code - BRENDANPETRILLI at check out and buy amazing Philadelphia merch here - https://phillydrinkers.com/ Watch Jason Kelce Tailgate with the best fans in the World https://www.youtube.com/watch?v=ZnT46Zp4lAc Watch my Phillies Vs Mets Game 2 Vlog Here - https://youtu.be/cT6rZRfcBVo?si=3fEQhf_Pd-NXq8Ge Watch more day in the life vlog here https://www.youtube.com/watch?v=tALDmoFfdgk Thank you for watching You can find more of my content here! Subscribe to Cold Ones Conversations - https://www.youtube.com/channel/UCVpcVAoFryI0gRvg71n0V4A Like, Comment and Subscribe Youtube - https://www.youtube.com/channel/UCyX9ie0ppKy4tC0eiZ92sxg Listen on Apple Podcast - http://anchor.fm/s/22f9b8bc/podcast/rss Listen on Spotify - https://open.spotify.com/show/389mOolRDa5dSvTkDSIVx8?si=43c15cf4eff3476e Follow me on all Social Media - Instagram @BrendanPetrilli - Twitter @BrendanPetrilli @BSP__Podcast - TikTok @BrendanPetrilli --- Support this podcast: https://podcasters.spotify.com/pod/show/bsp-podcast/support

Taking Control Of Your Diabetes - The Podcast!
Highlights from the Recent Diabetes Technology Meetings in Europe (ATTD 2024)

Taking Control Of Your Diabetes - The Podcast!

Play Episode Listen Later Apr 8, 2024 33:53


Join us as we talk about our experience at the 18th Annual Diabetes Technology Meeting in Europe (ATTD 2024). In this podcast, we'll be unpacking our favorite lectures from the event, which hold some very exciting data and insights. From cutting-edge advancements in diabetes technology to the latest developments in medications, we'll cover it all. Tune in as we explore the forefront of diabetes innovation and share our experiences from this meeting!In this episode, we will talk about:What updates are happening in diabetes technology? What are updates in diabetes medications? What is new with CGMs and Type 2 Diabetes? What is the silence all alert on your Dexcom G7? What is a continuous ketone meter and when is it coming? What is the most common cause of DKA in type 1's? What is time in tight range? What is Tzield (data information)? What is the new data on Afrezza? What is new information about SGLT2 inhibitors? What data information came out regarding Mounjaro? Show notes:Diabetes Technology Podcast - https://tcoydthepodcast.transistor.fm/47TCOYD Video Vault - https://tcoyd.org/tcoyd-video-vault/TCOYD Live PLUS Diabetes Technology https://tcoyd.org/live-feb-2024/?  ★ Support this podcast ★

Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives

In the third and final recap episode from the 17th annual International Conference on Advanced Technologies & Treatments for Diabetes, hosts of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives Diana Isaacs, PharmD, and Natalie Bellini, DNP, take a deep dive into a series of topics from the meeting, including GLP-1 receptor agonist use and CGM technology, updates in once-weekly insulins, the concept of continuous ketone monitoring, and application of artificial intelligence into care. Video version: https://www.hcplive.com/view/diabetes-dialogue-hot-topics-and-updates-from-attd-2024 

Diabetics Doing Things Podcast
Episode 273 - Rob Solo Minisode - Upcoming Events, ATTD Updates, Rob Life Updates

Diabetics Doing Things Podcast

Play Episode Listen Later Mar 27, 2024


In this episode of Diabetics Doing Things, Rob goes solo to discuss various upcoming events, including a diabetes meetup at Pax and Beneficia, where there will be a pour-over class and discussions on automated insulin delivery systems. He also delves into his experience at the Advanced Technologies and Therapies for Diabetes (ATTD) conference in Florence, highlighting key topics like access, adherence, and automation in diabetes care. Rob also shares personal updates on his diabetes treatment, goals for 2024, and insights from his Goldman Sachs program. The episode concludes with a quick discussion on Ramadan, upcoming events, and a call for mailbag submissions. Topics discussed: 1. Announcement of upcoming events, including a diabetes meetup at Pax and Beneficia with a pour-over class and discussions on automated insulin delivery systems. 2. Recap of Rob's experience at the ATTD conference in Florence, focusing on access, adherence, and automation in diabetes care. 3. Personal updates on Rob's diabetes treatment, goals for 2024, and insights from his Goldman Sachs program. 4. Mention of Ramadan, fasting with diabetes, and upcoming events like a diabetes legends basketball clinic in Dallas and Denver. 5. Call for mailbag submissions and updates on the podcast's content and goals. Key takeaways: * Events like meetups and conferences provide valuable insights and networking opportunities in the diabetes community. * Access to technology, adherence to treatment, and automation play crucial roles in improving diabetes management. * Patient voices are essential in shaping decisions in diabetes care and should be valued and compensated. * Personal accountability and structured programs can aid in achieving goals and personal growth. * Fasting with diabetes during events like Ramadan can present unique challenges, highlighting the importance of advanced diabetes management systems. * Engagement with the community through mailbag submissions and social media interactions helps in sharing experiences and raising awareness about diabetes. 00:00  Exciting Updates and Announcements for Diabetics Doing Things Podcast 00:26  Exciting Diabetes Meetup Event Announcement and Thriveable Partnership Details 03:38  March Madness, T1D Ballers, Clinical Trials, and ATTD Highlights: A Recap of the Diabetes World 13:38  Empowering Patient Voices at International Diabetes Conferences 18:10  Struggles with Insulin Access, 2024 Goals, and Ramadan Observance: A Personal Update 22:44  Exciting Updates on Diabetics Doing Things Events and Podcast Content Resources mentioned in this episode: * Pax and Beneficia Spring Meetup  * Thriveable * DCB and Tide Pool Clinical Trial * Rob’s Blog Post about ATTD * Dr. Addala’s Episode on DDT * #dedoc°

Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives
T1D Glycemic Improvement and CRISTAL at ATTD 2024

Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives

Play Episode Listen Later Mar 26, 2024 8:29


In this episode, hosts provide insight from automated insulin delivery updates from the 17th annual International Conference on Advanced Technologies & Treatments for Diabetes. The specific topics of note covered in this study include new data related to diabetes technology use from the Type 1 Diabetes (T1D) Exchange and a read-out of data from the CRISTAL trial.

Diabetech - Diabetes Tech, News, and Management
Where Diabetes Tech is Headed - Takeaways from ATTD 2024

Diabetech - Diabetes Tech, News, and Management

Play Episode Listen Later Mar 18, 2024 28:16


I attended the ATTD (Advanced Technologies & Treatments for Diabetes) Conference in Florence Italy to take a look at the future of diabetes tech.    Join Patreon for Exclusive Content   Fill out T1D Exchange Registry    Watch Video Podcast on Youtube    Follow David's Channels: Tik Tok | Instagram   DISCLAIMER: This podcast is not medical advice. Always consult with your doctor before making changes to your health care.    Follow for more: Instagram | Tik Tok | YouTube | Facebook

Diabetes Connections with Stacey Simms Type 1 Diabetes
In the News... ATTD updates, new CGMs, drops for diabetes eye disease, scholarships and more!

Diabetes Connections with Stacey Simms Type 1 Diabetes

Play Episode Listen Later Mar 15, 2024 8:45


It's In the News! A look at the top diabetes stories and headlines happening now. Top stories this week: The annual ATTD conference wraps up with news about CGMs, including new FDA approvals and a look at CGMs outside of the US, new eyedrops are being studied to treat diabetic eye disease and Beyond Type 1 opens applications for their annual Beyond Scholars. Transcript and links below Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com  

Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives

In the episode, hosts provide insight into sessions to watch, device news they are excited for, what makes ATTD a unique and valuable experience for the diabetes care team, and how the meeting's annual yearbook session encapsulates the exciting developments within the field. Video Version: https://www.hcplive.com/view/diabetes-dialogue-attd-2024-preview  Key Highlights:  01:05 - Bellini's ATTD Picks 03:45 - Isaacs' ATTD Picks 06:20 - Health Disparities in Focus 07:10 - Time in Tighter Range 10:20 - Insulin Users with T2D 11:15 - ATTD Yearbook Session

Diabetics Doing Things Podcast
Episode 265 - Rob January 2024 Solo Minisode

Diabetics Doing Things Podcast

Play Episode Listen Later Jan 31, 2024


Rob goes solo, Cracking at Coke ZerZ, and provides updates on recent and upcoming episodes of the Diabetics Doing Things podcast, his personal diabetes management, and partnerships with the North Texas Food Bank. He also discusses personal updates, including his experience with insurance coverage, a scholarship opportunity for individuals with diabetes via Skin Grip , and participation in the Goldman Sachs 10,000 Small Businesses program. Additionally, he shares plans to attend the ATTD event in Florence, Italy, announces new podcast partnerships, and introduces a mailbag Q&A segment for future episodes. Topics discussed: - Updates on the Diabetics Doing Things podcast - Partnerships with the North Texas Food Bank - Personal diabetes management and insurance coverage - Scholarship opportunity for individuals with diabetes - Participation in the Goldman Sachs 10,000 Small Businesses program - Attendance at the ATTD event in Florence, Italy - Introduction of new podcast partnerships - Launch of a mailbag Q&A segment for future episodes 00:03  Empowering the Diabetes Community: Updates and Impactful Initiatives 06:27  Navigating Insurance Challenges and Personal Updates on Diabetes 09:41  Exciting Updates on Business Ventures, Events, and Partnerships 14:22  Get Featured on the Diabetes Doing Things Podcast! References: - North Texas Food Bank: [Website](https://ntfb.org/) - SkinGrip: [Website](https://www.skingrip.com/) - Goldman Sachs 10,000 Small Businesses: [Website](https://www.10ksbapply.com/)

Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives

A recap of the top news and research from the 16th annual meeting for Advanced Technologies and Treatments for Diabetes in Berlin, Germany.

Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives
Diabetes Dialogue: Technology Guidelines and Uptake in Diabetes, with Grazia Aleppo, MD

Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives

Play Episode Listen Later Mar 1, 2023 22:25


In this episode, hosts are joined by Grazia Aleppo, MD, to discuss the development of guideline recommendations for diabetes technology as well as her top takeaways from the ATTD 2023 meeting.

Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives
Diabetes Dialogue: The Role of Patient Voice in Diabetes Management

Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives

Play Episode Listen Later Feb 28, 2023 19:17


In this episode, hosts are joined by Marissa Town, BSN, RN, and Renza Scibilia for a discussion centered around the role of the patient voice in diabetes management while on site at ATTD 2023.

Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives
Diabetes Dialogue: Actualizing the Optimal Role of Inhaled Insulin, with Joanne Rinker, MS, RDN

Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives

Play Episode Listen Later Feb 28, 2023 9:47


In this episode, hosts are joined by the associate director of Medical Affairs and Medical Education at MannKind for a special edition episode from ATTD 23 that focuses on use of inhaled insulin and future research plans for MannKind.

Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives
Diabetes Dialogue: Updates in Diabetes Management from ATTD 23, with Irl Hirsch, MD

Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives

Play Episode Listen Later Feb 26, 2023 22:46


In this episode, Irl Hirsch, MD, discusses a study he is conducting examining skin changes associated with insulin pump use in people with type 1 diabetes. Later in the episode, Hirsch discusses what he is most excited about in terms of ongoing and future research in diabetes management.

Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives
Diabetes Dialogue: Mental Health and PRO Standardization, with Katharine Barnard-Kelly, PhD

Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives

Play Episode Listen Later Feb 25, 2023 15:24


In this episode, hosts sit down with Katharine Barnard-Kelly, PhD, at ATTD 2023 to discuss the evolving recognition of the role of psychology in diabetes management for both pediatric and adult populations.

Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives
Diabetes Dialogue: Screenings for Hearing Loss in Diabetes, with Joanne Rinker, MS, RDN

Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives

Play Episode Listen Later Feb 25, 2023 8:12


In this episode from ATTD 2023, hosts are joined by Joanne Rinker, MS, RDN, who provides perspective on hearing loss in diabetes, including prevalence, the need for screening, and the underrecognition of auditory issues in the midst of a growing population of people with diabetes.

Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives

In this special edition ATTD Recap episode of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives, hosts Diana Isaacs, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP, and Natalie Bellini, DNP, FNP-BC, provide insight into their favorite sessions from the conference and clinical pearls they took away from their experience, including latest updates in the world of diabetes smart phone apps, smart insulin pens, and CGM systems. Also in the episode, our hosts react to Eli Lilly and Company's announcement of topline data from the SURMOUNT-1 trial in late April. 

Proactive - Interviews for investors
Arecor's Sarah Howell delighted with response to presentation at 15th ATTD conference

Proactive - Interviews for investors

Play Episode Listen Later May 4, 2022 9:19


Sarah Howell, Arecor's CEO, says that the presentation of phase 1 trial data for AT278, the company's ultra-rapid acting, ultra-concentrated insulin injection, was very well-received at the conference. What we saw in the trial hit the high end of our expectations, she said and demonstrated that despite that five-fold increase in concentration AT278 had a superior profile to the current standard of care. The next step will be a key opinion leader event on the 26th of May to explain the patient need for the product.

Diabetes Connections with Stacey Simms Type 1 Diabetes
In the News... ATTD News From Dexcom, Beta Bionics, Libre, Ypsomed & more

Diabetes Connections with Stacey Simms Type 1 Diabetes

Play Episode Listen Later Apr 29, 2022 6:29


It's “In the News…” Got a few minutes? Get caught up! Our top stories this week include headlines from the ATTD Conference - that's the Advanced Technologies and Treatments for Diabetes Conference. There's a bit of new information about the Dexcom G7, Beta Bionics announces it will release pivotal trial results, and news of the first AID system using the Libre 3 is announced. Along with ATTD there's news about type 2 diabetes and grocery stores, all types of diabetes and nursing homes and a person with T1D is on the cover of British Vogue. Learn more about T1D Exchange here  Join us LIVE every Wednesday at 4:30pm ET Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about AFREZZA* *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. we go live on social media first and then All sources linked up at diabetes dash connections dot com when this airs as a podcast. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX This week ATTD begins – that's the Advanced Technologies and Treatments for Diabetes Conference, so you can expect to hear a lot of news. I'll include some here, some next week and we've got future interviews lined up with a lot of the companies making headlines.. XX First up, a peek at more features in Dexcom's G7 system. It's approved in Europe but not the US and features what they're calling more meaningful alarms. You can silence more alarms, including urgent low & sensor fail for up to six hours, there's also a new 12 hour grace period at the end of the 10-day sensor life. It's already been announced the G7 has a much shorter warm up period, only half an hour, and is much smaller. -- Also at ATTD, Beta Bionics will be releasing Pivotal Trial Results of the iLet Bionic Pancreas. The iLet is a pump – connected to a CGM that is designed to autonomously determine and deliver insulin doses to control blood glucose levels. You'll recall this pump was originally designed to deliver both insulin and glucagon.. but the current iteration is insulin only. They says this pivotal trial population was more diverse and representative of the United States type 1 diabetes community than any previous pivotal trial of an automated insulin delivery system. We'll have more info on what these trials actually said next week. https://www.globenewswire.com/news-release/2022/04/25/2427846/0/en/Pivotal-Trial-Results-of-the-iLet-Bionic-Pancreas-To-Be-Presented-at-ATTD.html XX The first automated insulin delivery system using the FreeStyle Libre has been announced. This is in Europe and it's the Libre 3, Ypsomed pump and CamDiab software system. Expected by the end of the year, this is described as a self-learning app, a hybrid, closed-loop system that runs on an Android smartphone and can be tuned to users as young as one year old https://www.fiercebiotech.com/medtech/abbott-launches-diabetes-team-ypsomed-camdiab-bring-artificial-pancreas-system-europe XX And a new consensus meeting on Time in Range. In 2019, diaTribe formed the Time in Range Coalition, whose goal was to ensure that Time in Range (TIR) becomes the primary glucose metric for daily management, complemented by A1C, in diabetes care globally. But there isn't an internationally consensus on the use of CGMs in clinical trials. This meeting will help standardize those methods. XX Other highly anticipated – or at least well-publicized- studies coming to ATTD include those from Tandem and Omnipod and almost every big diabetes tech company. Lots more to come next week and we already have interviews set with Dexcom and Beta Bionics to we'll talk about all this in the long format episodes in weeks to come. XX Overtreating type 2 diabetes is apparently very common in nursing homes.. which can be a big problem as people get older and may require changes. New study in the Journal of the American Geriatric Society show about 40% of nursing home residents with type 2 diabetes may be overtreated. These researchers say one big issue is that at admission, residents are given a very big medical work up, but that isn't followed up on year to year. Often as people age, its recommended their A1C is maintained a bit higher, for safety reasons, so a target A1C could easily change years or even months after someone moves into assisted care or a nursing home. https://www.healio.com/news/endocrinology/20220422/diabetes-overtreatment-common-in-nursing-homes-with-little-medication-deintensification XX Right back to the news in a moment but first we've got a new sponsor. As I mentioned, The T1D Exchange Registry is an online research study, designed to harness the power of individuals with type 1 diabetes. It's a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy. Sign up at T1DExchange.org slash Stacey (that's S-T-A-C-E-Y). XX New survey looking at how people with diabetes rate their grocery stores. From D-Q&A this was a big survey, more than 5-thousand people statistically representative of all people with diabetes in the United States. They found more than half of people with diabetes did not feel very supported in maintaining their preferred eating habits at home. 28% of low-income people with diabetes find it somewhat or very challenging to find their preferred foods when grocery shopping. Stores rated best? Aldi, Publix, Costco, H-E-B, and Hyvee. The worst rated were BJ's, Vons, Shaw's, Ralphs, Tops & Randalls https://d-qa.com/major-grocery-chains-failing-to-meet-the-needs-of-people-with-diabetes/ XX Last year she made big news by walking the runway with her Omnipod visible, this year Lila Moss is – we think – the first person with type 1 on the cover of Vogue magazine. She did an interview with them that's on YouTube – I'll link up the video. She says she has an Apple air tag attached to her Pod PDM. Going through her handbag essentials, she included glucose tabs and talked about how her diabetes is something she doesn't keep hidden but just isn't always visible. Just nice to see a matter of fact interview featuring type 1. https://www.youtube.com/watch?v=5piEaumF6f0 XX On this week's long format episode, you'll hear from Civica RX – this is the company pledging to put out insulin without making a profit. We'll hear why they think this will work and how soon it'll be available for purchase. Next week we're talking about a new mental health conference for people with diabetes – it's virtual so you can participate from anywhere. Listen wherever you get your podcasts That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.  

Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives

In the April 2022 edition of Diabetes Dialogue: Therapeutics, Technology, and Real-World Perspectives, hosts Drs. Diana Isaacs and Natalie Bellini discuss the implications of semaglutide 2.0 mg (Ozempic)'s approval, the use of novel glycemic control metrics, and a preview of ATTD 2022.

Diabetes+ Praat
Afl. 11 - Henk-Jan Aanstoot over de nieuwste ontwikkelingen in type 1 diabeteszorg

Diabetes+ Praat

Play Episode Listen Later Sep 23, 2021 33:08


2 weken geleden was de ATTD, een groot symposium over alle nieuwe technologie binnen de type 1 diabeteszorg. Henk-Jan neemt ons mee in wat hij daar gezien en gehoord heeft. En dat is hoopvol.

Diabetes Connections with Stacey Simms Type 1 Diabetes
Dexcom CEO Kevin Sayer Answers Your Questions

Diabetes Connections with Stacey Simms Type 1 Diabetes

Play Episode Listen Later Jul 6, 2021 35:56


What do we know about the upcoming Dexcom G7? Find out in this conversation with company CEO Kevin Sayer. As usual we have a long list of questions from you covering everything from adhesives to watches to more. Sayer shares details about how they're preparing for the G7 rollout once it's approved, as well as issues with Medicare, integration with their current pump partners and when arms will become an approved wear site for US customers. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Dexcom G7 "sizzle reel" Get your diabetes gear to stick! Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Get the App and listen to Diabetes Connections wherever you go! Click here for iPhone      Click here for Android Episode Transcription below   Stacey Simms  0:00 Diabetes Connections is brought to you by Dario health. Manage your blood glucose levels increase your possibilities by Gvoke Hypopen the first premixed autoinjector for very low blood sugar, and by Dexcom help make knowledge your superpower with the Dexcom g six continuous glucose monitoring system. This is Diabetes Connections with Stacey Simms. This week, a Dexcom update from the company's CEO. As usual, we have a long list of questions from you covering everything from adhesives to watches to more about the upcoming G7.   Kevin Sayer  0:41 And the goal is to simplify CGM for everybody across the board. What I often say is everything you love about G6, you'll love more about G7. The size is so small, you don't really recognize it's on your body. It's really a great profile a little bigger than a nickel   Stacey Simms  0:56 CEO Kevin Sayer will also share details about how they're preparing for the G7 rollout once it's approved, as well as details about Medicare and use but their pump partners. This podcast is not intended as medical advice. If you have those kinds of questions, contact your health care provider. Welcome to another week of the show, always so glad to have you here. You know, we aim to educate and inspire about diabetes with a focus on people who use insulin. I'm your host, Stacey Simms, my son Benny was diagnosed back in 2006. Just before he turned two he is now 16 and a half my husband lives with type two diabetes, I do not have diabetes, but I have a background in broadcasting. And that is how you get the podcast. My usual disclaimer, whenever we have them on Dexcom is a sponsor of this show, you will hear their commercial later on. It's because we love the products. But when we have people from Dexcom on as guests to give you information, they don't tell me what to ask or what to say outside of that commercial. And I just want to take a minute to say I very much appreciate Kevin Sayer and others from Dexcom being so accessible over the years, you know, they don't always answer my questions, but at least they come on and address them and listen to them. There are a lot of companies that are very reluctant to even do that who won't come on the show. And that's really unfortunate because you as you listen, and you know the diabetes community overall, I'm very much entitled to speak to these people and to these companies. So I will keep pushing nicely, but I'll keep pushing, I promise quick heads up there will likely be no longer format episode like this one next week. I'm still gonna do the in the news episodes that I have added live on Facebook and then turning them into podcast episodes. But I am as you listen, if you're listening as this episode is going live, I met friends for life. I'm at the conference. They're having it again. I'm so excited. It's the first diabetes conference I have attended since February. No, since the first week of March of 2020. I went to a JDRF conference in Wilmington, just as COVID was beginning it was very weird. If you did anything any kind of public event in March of 2020. You remember that? But I'm back. They're back friends for life. And I really don't want to rush out an episode. But if anything exciting or you know breaking news happens or I'm able to record something and put it out I will but just a heads up likely no episode next week. Alright, and this week, not much of an introduction needed. Kevin Sayer is the CEO of Dexcom. And this interview focuses on some of what came out of the recent Ada scientific sessions and att D conferences. But mostly I share your concerns and your questions. We've covered a lot of these issues before, I don't ask a lot of follow up about things that in my opinion, you can easily Google up as usual, I had limited time with Sarah, who was doing back to back interviews. So if you have a specific question or if things went by very quickly, definitely jump into the Facebook group. You can comment on the post with this episode. We have some amazing members who will answer your questions Who will show you where to find the information. It's likely a previous episode, but we have people in clinical trials with people who were in on a lot of the investor calls they listened they take notes, they're fantastic. So if you haven't joined Diabetes Connections, the group on Facebook I highly recommend it. my interview with Kevin stay here in just a moment but first Diabetes Connections is brought to buy Gvoke Hypopen  and you know low blood sugar feels horrible. You can get shaky or sweaty or even feel like you're gonna pass out. There are lots of symptoms and they can be different for everyone. I am so glad we have a different option to treat very low blood sugar Gvoke Hypopen is the first auto injector to treat very low blood sugar Gvoke Hypopen is pre mixed and ready to go with no visible needle. Before Gvoke people needed to go through a lot of steps to get glucagon treatments ready to be used. And this made emergency situations even more challenging and stressful. This is so much better and I'm grateful we have it on hand. Find out more go to Diabetes connections.com and click on the Gvoke logo Gvoke shouldn't be used in patients with pheochromocytoma or insulinoma visit Gvoke glucagon dot comm slash risk. Kevin Thank you so Much for jumping on with me another busy time for you as so many presentations, lots of studies, lots of news, lots of upcoming and anticipated news. So I appreciate you spending some time with me and my listeners. Oh, thank you for having me. It's always fun. Let's set the table a little bit here. We are following up on the ATTD conference and you are in the midst Dexcom as we're speaking of ADA, this is all still virtual though, right?   Kevin Sayer  5:25 It's all still virtual. Yeah, I was looking was hopeful earlier this year, it might be in person, but not yet, probably not till next year.   Stacey Simms  5:33 Well, as we look through the news that is coming out of both of these conferences, I could just start out by saying it's kind of I'm not sure victory lap is the right phrase here. But it does seem that almost every study is basically Kevin CGM works, it's good. It helps we get better outcomes from it. So let me just give you a moment to talk about some of that. Because there were so many we can't really touch on all those studies.   Kevin Sayer  5:58 There are so many studies, and it's good for a number of different groups as well. You've got all the automated insulin delivery studies, and other the Medtronic product all these other studies are powered by Dexcom. You've got stuff in the UK, France, Insulet Tandem in the US, there's a lot of good news on the automated insulin delivery system front. And all these works are powered by Dexcom G6 right now, you've got studies that we presented at att last week, or that were presented by physicians that were very well aware of the mobile study, which was for patients with type two diabetes who are on basal insulin only. You know, when you start a study like that, it's kind of a risk, because you asked yourself the question, what happens if it doesn't work? Well, it works. And what we learned is these patients, even though they're not making a decision every four or five, six hours, because for eating, they are making decisions about what they eat, and what they do and how they exercise when they can see data. And they can see the effects of what goes on in their lives. And their timing range goes up significantly, if they can see what their time and range is, you know, they've been operating in the dark, and people would argue that they don't need it all the time, like I do. And so that study, we think is just really good and will be the basis, hopefully someday for getting CGM coverage for that group of patients. And so we'll push on that one. There was another study we had last week, or at ATD. Early in the month, published in Belgium, where a coalition of diabetes gurus I guess over there's best icon, it's really all the leaders in the Belgian diabetes community took a bunch of intermittent CGM users and put them on Dexcom G6 for an extended period of time. And then we've looked to see what happened. And what we saw is on real time CGM, the patients are better in every category, every single category, time and range, hyper hypo, you name it, they did better. So we really did validate the Dexcom equation over competitors with that study. And we think it's very important. I realize real time CGM, it is important, it is important to data be accessible. And the alerts are something that you can use. There are other studies being presented by other people in the type two who are reading Kaiser's got a study where they show patients do well on doulas got several studies, they're across the board. And the evidence is building for these other markets. But it starts at the beginning, obviously with automated hands on delivery and, and we work our way down. But we've had information presented across the board showing the utility of Dexcom. And if you've been to this study 10 this meeting 10 years ago, like I was when I first started here, my literally my first month was my first Dexcom ada, nobody even knew who we were. And those who did said yeah, products not real great. So times have changed pretty dramatically.   Stacey Simms  8:41 Do you remember what what that first study that was presented at ADA or ATTD? which one it was that you were there for 10 years ago? I'm curious that back in the day,   Kevin Sayer  8:50 yeah. First study, we didn't even present studies. Back then we, I will tell you the most important study we did, we did a study in where we first got ADA recognition, we did a study with our G4 system against a competitor in Europe. And we got a bunch of recognition there. And then the next study that really got us a lot of recognition in Ada meeting was our diamond study where we show the people on multiple daily injections. If they went to CGM, they would get much better results. What it was hard for me to learn is you don't say I want to do a study like this and get it done in a week. It takes a couple of years to accumulate all the proper data, process it develop all the subsets and everything. And so my patience has been has been level set with respect to studies like this. And there's multiple studies going on in the field that will be present over the next several years.   Stacey Simms  9:44 All right. Well, that's a really good segue to moving ahead, because, as you know, my listeners are very interested in this technology. And the slide that probably got the most attention in our groups was one that was presented at ATTD about introducing the Dexcom G7, showing all of the features of this. So let me I'm not going to go through all of them, obviously. And you and I've talked about this many times before, but faster warm up. It's smaller, simple application all in one. This is all still part of the plan, as we had talked about before. Yes. Okay.   Kevin Sayer  10:20 Yeah. And, you know, we started working on the G7 before G6 was even in clinical trials. The G7 is a project we've envisioned for a long time, verily, actually was Google Health before then, verily was a partner with us in designing this product, and we working out for quite some time. And the goal is to simplify CGM for everybody across the board, what I often say is everything you love about G6, you'll love more about G7, the size is so small, you don't really recognize that it's on your body, it's really a great profile a little bigger than a nickel. It we're running this study with arm and abdomen indications. And while patients were in wherever they want, we're going to show you that it can be worn wherever you want. And I think that's a big deal that we go ahead and do the work to do that. The faster warmup is kind of mind blowing when you put a g7 up and then you look after you pair it. And then you look and say you only got 25 minutes left, it's like, oh, wow, I don't have to do the two hour countdown. You know the accuracy and performance that Jake presented. ATTD shows that we're not, we're not ever going to go easier on the performance side and say good enough, we always push ourselves to offer something that will keep people save and confident with what they have. The app is completely new, we'll build things into the app over time, like automated, the frequently asked questions feature we have now but we're just gonna keep making it better. Some of the features of our clarity system will ultimately be in the app. So you'll get more information. When you go to it and look at it out of the get go. You know, we'll get it approved. It'll be a while before our partners have integrated their systems. But we're working with Insulet and Tandem already on G7 integration, I it'll be able to talk to multiple devices at the same time. Its manufacturing cost, ultimately will be less expensive. It's been designed for an automated process. And we've got fully automated lines up and running to assemble the G7 sensors we have in fairness to have automated G6 lines up and running now to but we've got special transmitter lines and center lines and different those kinds of things. It is going to be a really the most advanced CGM ever   Stacey Simms  12:25 Well, you've touched on a couple of listener questions already in that testing alternate sites, including arms integration with the systems that are already using G6, so I don't want to spend a lot of time going in depth on things that you've mentioned. But in the slide it said direct to watch capability.   Right back to Kevin clarifying what was meant in that slide. But first Diabetes Connections is brought to you by Dario Health and bottom line you need a plan of action with diabetes. We've been lucky that Benny's endo has helped us with that and that he understands the plan has to change as Benny gets older, you want the kind of support to take your diabetes management to the next level with Dario. Their published Studies demonstrate high impact results for active users like improved in range percentage within three months reduction of a1cwithin three months and a 58% decrease in occurrences of severe hypoglycemic events, try Dario's diabetes success plan and make a difference in your diabetes management. Go to my daario.com forward slash diabetes dash connections for more proven results and for information about the plan. Now back to Kevin Sayer, answering my question about what the company means when it says the Dexcom g7 has director watch capability.   Kevin Sayer  13:44 capability. Yeah, it won't go there first pass. But we had to have different electronics and a different radio set to go director Watson what we have in G6. And it's easier to get us to change and is to get Apple changed or to change their watch. And so as we were doing the g7 system, we did contemplate that. So it is configured to do so I do not believe it's in the first release. But it will be not long after that. We'll have a direct watch capability. And we know people really want to watch presents interesting problems. And we can all sit and say we want that. But you have to charge your watch every day or at least every 36 hours. Where are you getting your alerts if you're direct to watch and it's on the charger. And you're in different parts of your house. There's complexity sit a watch that go far beyond just direct to connect. And particularly with the FDA who've used the alerts in the alarms. I think connectivity is so important that we had to make sure we do it right. So we'll work on that and get it wired appropriately. But I look I know what something I would want If I were a user. So I we continue to push for it.   Stacey Simms  14:44 Just to follow up on that. When you say it won't be in the first iteration of it. But you know, it'll it'll be it's capable. It'll come that it kind of implies that you figured out what to do with the alerts and alarms when someone hangs it up to charge.   Kevin Sayer  14:56 I don't know what they have figured out. I just know they're addressing it. All right. I have to plead the fifth, I just as I've asked that question, they said, Well, here's a problem. How are you going to deal with that? I said, Well, you guys don't have to tell me. They'll come up with the right answer I   Stacey Simms  15:09 So I'm sure they will, but to say direct to watch capability, there's a little parentheses that says when we figure it out, oh, wait, I know we're working on but   Kevin Sayer  15:17 okay. But Stacy, we couldn't even go direct watch before with the electronics. We couldn't go direct to watch with a G6 transmitter, the g7 electronics stack and configuration is such that it can go direct to the watch, we could not watch G6.   Stacey Simms  15:32 Okay. Many more questions. My listeners are very, of course interested in the adhesive changes is the G6, two G7 change. I know you're addressing this in your testing, we've got emails from people who are in different trials for adhesive and reactions and things like that. And I have lots of questions people say it's getting better other people say it's getting worse. Anecdotally, it's very difficult, obviously, for me to now talk to you a little bit about those changes and how it's improving.   Kevin Sayer  15:58 Well, we've tested numerous adhesives before we landed on the adhesive we we selected for g7, one of the reasons we kept the product life down to 10 days is to make sure we have enough adhesive to get to that 10 days, we'll be putting the overpass in every box. So if somebody wants an overpass, they don't have to call us. So everybody should be thrilled with that one. And it's quite easy to use, we're hopeful that there's no allergy. With G7, somebody's always gonna have a reaction does just physiology, but we're working with new tapes for G6 already, where it will hopefully have something the things that cause a lot of the allergic reaction in G6, we've eliminated from the G7 manufacturing process. So we're hopeful that a lot of this stuff goes away on its own, we'll monitor it very quickly. But we've already got four or five other g7 adhesives in test in addition to the ones that we're going to launch with, to make sure we can create better options in the future if we need to. So you know, stay tuned on that one, we are comfortable. As I sit here, we will not have the same level of reaction that would have at G6 when we change it. But yeah, we won't know till we're out there. Yeah.   Stacey Simms  17:10 And you mentioned the 10 day were and part of that being you for adhesive. But my understanding is that the idea is for 14 day wear for Dexcom. She said eventually,   Kevin Sayer  17:19 eventually, eventually not again, that first pass or get it approved with 10 day data, very important to us is that we provide our customers with the experience they paid for and they signed up for. And we've looked at competitors reliability data, how many make it out to 14 days, or how many make it seven days if they only have seven, and we look at, it's one of the key management indicators, we monitor how many of our sensors are making it out to 10 days, and we've set a pretty high bar for how we want our system to work. And while we could have lost a longer lasting product, we wouldn't have hit the percentages with the configuration that we have. And so we said, OK, 10 days is enough. Our patient base is fine with 10 days as long as we deliver on the 10 days that we promise. And we'll get into longer live trials literally as soon as we're done with these and hopefully move it over. Because that does cost us a lot less and give us more pricing flexibility over time for the various groups. But for now we'll go 10 days, mainly, so we have more reliability. That's the biggest reason.   Stacey Simms  18:22 I have a few more G7 questions, but they're about pricing and accessibility, why?   Kevin Sayer  18:26 You know what I can I can answer most, okay, because we can't really go address pricing until it's approved. Right. And we have as we put our G6 contracts in here together over the past couple of years done so in anticipation of a g7 product to whereby, for example, for Medicare, it's a fixed charge per month. And for many of our insurance contracts, it's resembling more that type of business arrangement, we're hopeful that we can transition to g7 very quickly. But we will have to go to all your payers and get G7 covered before they'll pay for it. We're hopeful that'll be a quick process. But in the meantime, G6 is a great product and people will be able to use it, I can't give you a timeframe as to how long it'll take will have to go to CMS will have to go to all the Medicaid groups as well, what we're trying to avoid. And let me repeat what I don't want to deal with is one of the things I dealt with with the G6 for a long time, we didn't have enough inventory of production capacity to get it to every group. So the Medicare population was stuck with G five for quite some times those emails were not good. We want to make sure it's equal access when we can get it in the channel for everybody. And we're trying to build that type of capacity.   Stacey Simms  19:34 A couple of what if questions, just kind of looking down the road JDRF recently announced that they are looking for and this is the very beginning. So as you listen or as you're watching, this is not in the works yet. This is a call for research that they are looking for a CGM that could also measure ketones, and I haven't seen any companies step up yet publicly to say yes, we're working on that we'd like to be part of that is that Anything that Dexcom is thinking of doing.   Kevin Sayer  20:02 We've explored this for quite some time long before the JDRF initiative. And the question I keep asking, is continuous ketone measurement important that we know that for the pediatric world that if you measure ketones continuously, you might predict dangerous decay moment before it happens. But at what cost to the system? And is there a cost benefit associated with this? So we're setting all those things? We're in the learning phases, we think we have a platform that can do that. But we've got to decide do you sacrifice glucose accuracy? If you throw a ketone sensor on there? There's a lot of answers. We don't have yet. But we're in the early phases. And we've talked with JDRF and others about it, is there a better way to measure ketones that might be easier and less expensive? I don't know. We've looked at several other analytes to go with our system over time. And I think in the future, that'll be some but that's not coming from us for at least three years, if not longer.   Stacey Simms  20:57 You've looked at other analyze satellites, tell me about what else has been looked at just for free? No.   Kevin Sayer  21:03 Well, I won't go into all of them. I certainly look at lactate from a stress level. And for physical fitness, for example, there are a lot of athletes, you'd like us to produce a lactate sensor to whereby they can measure the progress of the physical fitness. There's also used for lactate in the hospital environment with we think with respect to predicting things sepsis over time, but those are you know, that's one of them. And we've looked at a few others and fail, I won't go into all those. We've looked at some that may be promising. What we find from time to time is Yeah, what we'd love to measure but we can't is insulin on our wire. There are any way we could measure insulin in addition to glucose, wouldn't that be awesome? We know exactly how much insulin you have on board. And we know exactly Well, we can't we we've not been successful at that one that would require a different technology than what we have. So we look at all of them. And over time, we think we'll have some some good stuff there. But not for a while.   Stacey Simms  22:00 Um, you know, you mentioned hospitalizations. And last year we talked about the CGM program in hospitals. I forgive me I, there were so many studies at ADA and ATTD. I don't know if this was presented. But let me ask a general, how is it going? Are hospitals adopting and adapting to you are   Kevin Sayer  22:16 they are adopting and adapting is harder than adopting? Yeah. Because, you know, this is a device that was designed for your listeners. And for you. It wasn't designed as a device that was designed to be used in a hospital room with all of the cybersecurity and connectivity issues of a hospital. Where do we send the information? How do we get it there. And and so we've got to solve the workflow issue to make this meaningful in the hospital environment. Over time, what we have learned is our technology is more than good enough to go there. And that the places particularly where you have an endocrinologist very heavily involved in treating the diabetes patients in the hospital rather than a cardiologist or somebody else, when there's an endocrinologist involved, we can go very quickly, they can learn some of the hospitals would take an approach, let's put this on everybody. Others would only take an approach. Let's put this on severe cases. So there have been different protocols used. But by and large, the response to CGM in the hospital has been very, very good. And we think it is a great market for us over time, we got to work on the proper configuration for workflow. I mean, one of the best examples, how do you get the data to the medical record? Because everything in the hospital goes to the medical record? How do we make that seamless? We haven't figured that out yet. And that'd be important for all of our users even outside the hospital. Imagine how much easier would be to go to your doctor and have your Dexcom date already sitting in the medical record when you get there? We're not there yet. But we're having a lot of good discussions on that front.   Stacey Simms  23:42 One of the topics that's been kind of in the community recently, and I don't think it's so much Dexcom. But I want to ask you, anyway, is this issue of and you mentioned, athletes who want to measure certain things of people without diabetes, using Flash glucose monitoring, or continuous glucose monitoring? I'm curious is that a market that Dexcom is looking to pursue? I mean, the g7 is smaller, it's lighter. And you know that I'm asking this because we've talked many times before, people who use insulin, are very much afraid of not being able to afford being left behind if many, many, many people who may not use it in the same way, started adopting these products.   Kevin Sayer  24:19 Let me address that in a couple of steps. Let's talk about the use case. First. There are people a lot of people using Dexcom, who do not have diabetes as a health and wellness tool. And there are a number of apps that are being developed that require glucose information to level set your nutrition now possibly type two diabetes or pre diabetes, but there are groups and some groups with some very interesting ideas as to how to change your diet based on glucose data to make you healthier. We were used many years ago on the biggest loser with every patient that came in the door and the one of the production people I don't remember which one might have been the physician came to me and said you need Yeah, the diabetes business you can make a lot For many weight loss fall, we're not getting out of the diabetes business, that's where we are and where we stay. One of the things we've contemplated with g7 is the fact that we're going to go to more people. And we're going to go to more people than just the type one population, we plan on having capacity to build over 200 million sensors, before the end of 23 200 million sensors, you can be more than enough for the intensive insulin using community. And as far as cost will cost comes down, if we can sell that much in volume. Now,   Stacey Simms  25:30 you're in the American healthcare system. Kevin, you know, this is not a market based device, we don't, I'm more, I'm more felt like, I'm sorry,   Kevin Sayer  25:39 let me keep going. At the end of the day, as you look at what somebody pays for taking care of themselves with delivering insulin and powering insulin pump, that's a very complex task that requires a lot of customer service and support. If somebody is only losing weight, that's a different problem we're trying to solve, or if somebody is trying to titrate a type two drug, that's a different problem, I think we can find a way to make everybody happy, I don't think we're gonna disappoint anybody. And we planned this company and built this company to make sure that we have capacity to do all this, it's, you know, it is, one would look at me, I mean, we're gonna spend over a billion dollars on these factories over the next two, three years here. This is not a simple endeavor, it is a large investment. And this technology first goes to the community that we serve. Now worldwide, we have to expand worldwide, but get it to the group in the US as well. After that, we'll go the other places, but we're going to have more than enough capacity to do that. In fact, one might question if I'm insane, or we're insane to create so much capacity and the 200 million, quite candidly, the wave design the g7 lines, if we need to sample at a factory, we can do it very quickly. So this is a, this is a long term play for us. We believe this technology be beneficial to a number of people. And so if we can get if we can get all these sensors out there and all these uses, I think it'll be it'll benefit your audience while it'll detract from   Stacey Simms  27:00 I know, we're going to run out of time. I've got two more questions. You've mentioned,   Kevin Sayer  27:03 you got them all give you time for two questions. Let's finish. Alright, here's what you want.   Stacey Simms  27:09 You mentioned already, lots of different apps are being developed not all diabetes. You know, a couple years ago, Dexcom announced the availability of the API, you know, developers can get data through third party apps. I'm curious, is there anything going on maybe behind the scenes? Or are you doing anything further to kind of foster more innovation in the early stage, like the development of other companies? Or is that a thing of   Kevin Sayer  27:30 the past? No, I'll give you two things that we're doing. Number one, we have a live API use where you can have a live display of the data that's on file with the agency right now, it'll eventually get approved. So you'll be able to run the Dexcom app, did it go the cloud comes straight down to another one. I think that is a very good use of the technology. And it shows our willingness to work with others. So that is a good use. One of the other things we have coming, then we'll see where it goes. Our intended use case in the beginning was with major healthcare systems. But we have another app that we've shown pictures of it's an app inside an app. So let's say for example, you go to scripts here in San Diego, pick scripts, and scripts has their own healthcare app. And they also want to be the center of your diabetes care, particularly for type two diabetes, and they might have you wearing a sensor for something other than isn't delivering, we've developed an app that can reside inside another app, to whereby you can have your scripts experience, but you can touch an icon and you go to a Dexcom experience. And it, it's an app that resides inside the app and for security, we're able to keep others out that app inside the app concept is nothing we've done to commit to others, to give them an opportunity to use Dexcom technology in a different way. And yet preserving create their own experiences. We're very cognizant of the fact that we can't solve every problem, and there might be better experiences. And we can create. Okay, got time for one more.   Stacey Simms  28:54 All right, last question. And it's more of a request. But the question is when you can This is from a couple of listeners, when you start rolling out the g7. any consideration for including and this may be an insurance question to one extra sensor a year. So three and a month?   Kevin Sayer  29:10 What a wonderful question. And let me tell you something, we spend an inordinate amount of time analyzing sensor failure and returns and those types of things. We have run models that say if we give everybody if we just gave everybody x more sensors a year, we could avoid all the phone calls and all of the issues and all that stuff. We analyze this warranty policy all the time. And I think what you'll see with with G7 will have better tools, my hope someday just for your users, I would love to just diagnosis in the app in general, to whereby if your sensor fails, we know when we say your sensor failed, tap on this icon to get a new one. The flip side of that is we have a business to run and we can't do all free centers. So if it comes to the time if you buy 12 months for the sensors, and pay for 12 months for the center's let's make sure you get 12 months where the US If that means we ship you a free one because one failed, that's fine. But we're still, you know, we found one patient in another country, I won't say which one, they got 48 free sensors and purchased all of three, because they spent all this time. Those are the far exceptions from the rule, people will just want care. And so we are doing everything we can to come up with better policies to make it easier for you. because quite honestly, those phone calls cost us way more money. And they cause you guys frustration, we are going to make this better over time. That's a promise I can make. And let's talk about it. In a future conversation. I'll tell you some of the things we've done. All right,   Stacey Simms  30:36 well hold up for a baker's dozen one of these days. But Kevin, thank you so much. You're always very accessible and on there really do appreciate your time.   You're listening to Diabetes Connections with Stacey Simms. Lots more information at Diabetes connections.com. If you haven't seen it yet, a while back Dexcom sent me what they call a sizzle reel of their G7 what it looks like. So I'll put that video in the show notes as well. We have a YouTube channel. I don't put a lot of extra stuff there. But things like that Dexcom video, and the in the news, you can watch it if you'd prefer, I always put that on YouTube. And all these episodes are there as well, although they're mostly just the audio, but a lot of people listen, watch, they listen that way on YouTube. So that'll be linked up in the show notes. And I realized I haven't mentioned it on the show yet. But you know, this time of year getting your Dexcom or getting any gear to stick can be difficult lots of wet and sweat in the summer. And I've created a guide, seven top tips to get your diabetes gear to stick in the hot summer. Over the years, we've tried so many things. Benny has had a pump since he was two. He's had a Dexcom since he was nine. So a lot of you know trial and error. And this guide is available absolutely free. So I will put a link in the show notes. If you get the newsletter, you may have already seen it. But just in case you don't. And the show notes are always at Diabetes connections.com. Every episode has its own homepage with a transcription started that in 2020. And we are working our way back. If you're listening on a podcast app, there are shownotes there but in case you have problems with links or whatever, you can always go to the episode homepage. And as I mentioned, Diabetes Connections is brought to you by Dexcom. It is hard to remember what things were like before we started using the Dexcom I just had when he was nine, right. But he had diabetes for seven years before we started using it. And I guess I haven't really forgotten what that was like. But it's just so different. Now, when he was a toddler, we were doing something like 10 finger sticks a day. And even when he got older, we still did at least six to eight every day more when he wasn't feeling well or when something was off. But with each iteration of Dexcom we have done fewer and fewer sticks. The latest generation the Dexcom gs six eliminates finger sticks for calibration and diabetes treatment decisions. Just thinking about Benny's little worn out fingertips makes me so glad that Dexcom has helped us come so far. It's an incredible tool. And then his fingertips are healthy and smooth, which I never thought would happen when he was in preschool. If your glucose alerts and readings from the G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions. learn more, go to Diabetes connections.com and click on the Dexcom logo. As I mentioned at the top of the show, I am at friends for life right now as you're listening. If you're listening as this goes live on the day that it goes out there, I'm traveling to friends for life, and I'll be here for the week. If you're not familiar. This is the largest family diabetes conference in the country. It takes place every July in beautiful Orlando, it's so hot, but it's a great time it's on the Disney World property. I don't usually go to the parks if my kids aren't coming. They they're not coming with me this year. So I doubt I will be going into a Disney park. But it's a fabulous conference. And I just want to let you know I'm doing a new presentation. I'm working up some new stuff. I'm very excited about it. And this one is called reframe your diabetes parent brain. And I gotta tell you, I am really sick and tired of seeing people berate themselves and talk about mom fail and tell themselves how terrible they are as parents. So this is going to be a session where we talk about the mistakes we've made. But then I want to help people reframe them so that they see what they've learned. You know, my whole philosophy is you mess up and you learn. And that's what this is all about. So I'm really excited to try it out. We're like overwhelmed. I don't know. You know, I think so many diabetes parents are so wrapped up in perfect now that they feel like if they go above 120 or 150 that they failed their children. So, gosh, I feel really passionate about it. And we're going to try that. And then for the fall, I've been getting a lot of questions about sending kids to camp, and I've gotten more and more of these over the years. You know, how do I send my type one kid to regular sleepaway camp. So I'm working on a presentation about that because fall, August, September is when a lot of people sign their kids up for next summer. So as you listen if you were affiliated with a group that does meetups or zoom calls, or in person And conferences, let me know I would love to speak to you and start these dialogues and help you really help your kids thrive with type one. We're not done. We're far from done right, Benny 16. But you know, he's a confident and happy kid. So knock wood. Where's all my wood to knock? I say all the superstitious stuff, right? I mean, I don't kid you know how superstitious I am. But I really hope that I can help other parents. You know, the idea here is not that you don't worry. The idea here is that you do it anyway. All right. Thank you so much for joining me. Thank you, as always to my editor John Bukenas from audio editing solutions. I will see you back here in a couple days for the in the news episode, but again, no long format episode, the following. Alright, I'm Stacey Simms until then, be kind to yourself.   Benny  35:49 Diabetes Connections is a production of Stacey Simms Media. All rights reserved. All wrongs avenged

Diabetes Connections with Stacey Simms Type 1 Diabetes
In the News... Apple drops a BG hint, Dexcom G7 update, Omnipod 5 study and more!

Diabetes Connections with Stacey Simms Type 1 Diabetes

Play Episode Listen Later Jun 11, 2021 8:07


It's "In the News..." the only LIVE diabetes newscast! Top stories this week: -Apple drops a BG hint in the latest watch update -New info about Dexcom's G7 -Omnipod 5 study released -Diabetes drug shows promise for weight loss -Power of peer support Join Stacey live each Wednesday at 4:30pm EDT at https://www.facebook.com/diabetesconnections Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Get the App and listen to Diabetes Connections wherever you go! Click here for iPhone      Click here for Android Episode Transcription below:    Hello and welcome to Diabetes Connections In the News! I'm so glad you're here! I'm Stacey Simms and each week I'll share the top diabetes stories and headlines of the past seven days.  Whether you're joining me live on Facebook or watching or listening after, I'm here to get you up to speed quickly on what's happening with diabetes technology, research, and our community. Since these are headlines and summaries, as always, you'll find all the sources and links in the Facebook comments and in the show notes at d-c dot com. XX In the News is brought to you by Inside the Breakthrough. A new history of science podcast full of “Did You Know Stuff” XX here's what's In The News this week… Couple of buzzy slides from Apple's World Wide Developer's Conference. First, this one from their WatchOS 8 update.. they didn't use the words blood glucose.. but this slide was shown featuring the graphic “blood glucose highlights.” That likely means pulling the data from existing apps like Dexcom or Dario or One Drop, but there are always rumors about Apple releasing a glucose sensor of their own.  We shall see – thanks to Nerdabetic for bringing this to our attention. Another diabetes shout out in this slide - same presentation - about time sensitive notifications. If you look closely you can see the Happy Bob app, which puts funny messages along with glucose notifications. XX Lots of news out of the recent Advanced Technology and Treatments in Diabetes Conference or ATTD. Dexcom showed this slide about their upcoming G7.  We've reported on this a lot over the last two years, I'll link up our previous episodes. but the new info includes: a 30 minute warm up time as opposed to 2 hours right now, and direct to watch capability. Direct to watch from Dexcom – that means you don't need your phone to see your BG on the watch face anymore - was first announced in June of 2017 with the G5 and that proved more difficult to implement than expected. I'm talking to Dexcom for the podcast later this month so we'll get a update on what this really means. The G7 is a smaller, all in one with sensor and transmitter applied together. It's NOT FDA approved yet so there's no timeline for release. Also, Dexcom put out a study that says people with type 2 who use basal insulin benefit from the use of CGM. The Mobile study took place over eight months. Those who used the CGM increase time in range and showed a full point drop in A1Cs on average. https://twitter.com/ATTDconf/status/1401200753717432328 New data presented on Omnipod 5.. this is just an abstract – full study will be released later this month. This is Insulet's hybrid closed loop system where it works with the Dexcom to keep a user within a targeted blood sugar range. They looked at children and adults ages 6-70 to measure safety of this new system. A1Cs came down, time in range went up, very low occurrence of hypoglycemia and researchers concluded it was safe. The Omnipod 5 operates in two modes, an automated mode and a manual mode. The system provides automatic insulin delivery with customizable glucose targets from 110 to 150, which can be adjusted by time of day. Omnipod 5 with Horizon is in front of the FDA right now so there's no timeline on release.   https://care.diabetesjournals.org/content/early/2021/05/21/dc21-0172   Also at ATTD - DarioHealth looking at outcomes from their highly personalized apps and system. Dario's study found that personalizing the clinical interventions in response to unique individual actions really helps. That's opposed to systems with more generalized predictions. This study showed more frequency in blood sugar testing and monitoring in those who received an personalized intervention. https://www.prnewswire.com/il/news-releases/dariohealth-releases-study-demonstrating-the-impact-of-personalized-digital-interventions-to-improve-self-management-of-diabetes-301305650.html XX Early on here but a new closed loop system that knows when you're eating is being tested – this was a small trial in adolescents and young adults. This is out of UVA – the same place that developed what became Tandem's Control IQ. The researchers say teenagers are particularly prone to skipping meal boluses. This system, known right now as Rocket AP contains an Artificial intelligence bolus priming system that uses CGM to basically decide if you've eaten without bolusing. If it thinks you have, it will automatically dose. The median time in range after a bolused meal was 100% with the Rocket AP system and 93% with the control system, but was a corresponding 83% versus 53% after a meal without a bolus. Again, that's 83% time in range when you completely forget your meal bolus. Bears watching. https://www.medwirenews.com/diabetes/ai-fully-closed-loop-insulin-delivery-type-1-diabetes/19231866 XX Up next.. a diabetes drug is approved for weight loss but first.. quick break – want to tell you about one of our great sponsors who helps make Diabetes Connections possible. Inside the Breakthrough is a podcast that mixes historical wisdom with modern insight – it's a science show that's also entertaining. I love it. The latest episode talks about scientists who knew they were onto something but needed to see things with their own eyes. How actually seeing something like a Kraken? Makes a huge difference. It also meant a name change for what some thought had only been a myth. And this actually relates to diabetes! Listen to Inside the Breakthrough wherever you listen to podcasts.. Back to the news…   The FDA has approved the medication Wegovy (wee-GOH-vee), a higher dose of the diabetes drug semaglutide (semuh-GLU-tide), to be used as a weight management drug in patients with obesity. It's the first drug for chronic weight management that has been approved by the FDA since 2014. It is injected under the skin once a week. People in the study lost an average of 12 percent of their body weight. People with type 2 diabetes lost 6 percent of their body weight. No reason given for the difference and there are some – intestinal side effects – but Wegovy is said to be safer than older weight loss drugs. https://www.healthline.com/health-news/fda-approves-popular-diabetes-medication-for-use-as-weight-loss-drug   XX The power of peer support was shown at ATTD in a presentation by Kelly Close and Diatribe. Their survey showed engagement in the diabetes online community didn't just make people feel better emotionally, which is great, but it also predicted better glycemic outcomes.. those most involved in the community increased their chance of having an A1C under 7. That's Diabetes Connections – In the News.  If you like it, share it. And feel free to send me your news tips. Stacey @ diabetes dash connections dot com. Please join me wherever you get podcasts for our next episode -Tuesday – we're talking to the folks from Beta Bionics for the first time in a long time to get an update on the iLet pump. And the episode that's out right now is all about what college students want you to know. Thanks and I'll see you soon

Pharma Intelligence Podcasts
Device Week, 9 June 2021 – ATTD Medtronic Update; CVRx IPO

Pharma Intelligence Podcasts

Play Episode Listen Later Jun 9, 2021 6:27


In this week's podcast, Medtech Insight's UK-based reporter Barnaby Pickering provides an update on Medtronic's MiniMed 780G insulin pump cost-savings study, presented at the Advances Technologies & Treatments for Diabetes (ATTD) conference. US Commercial and R&D manager, Reed Miller, highlights details on CVRx's recent IPO. Medtech Insight articles addressing topics discussed in this episode: ATTD 2021: Despite High Upfront Cost, Medtronic's 780G Could Offer Cost Savings https://medtech.pharmaintelligence.informa.com/MT144044/ATTD-2021-Despite-High-Upfront-Cost-Medtronics-780G-Could-Offer-Cost-Savings CVRx Raises $75M In IPO To Commercialize And Develop Heart Failure Therapy https://medtech.pharmaintelligence.informa.com/MT144039/CVRx-Raises-$75M-In-IPO-To-Commercialize-And-Develop-Heart-Failure-Therapy For more information on Medtech Insight and to start a free trial, click here: http://bit.ly/2w7LnlR

Diabetes Connections with Stacey Simms Type 1 Diabetes
In the News: Could a CGM measure ketones? D-Tech in the hospital and more...

Diabetes Connections with Stacey Simms Type 1 Diabetes

Play Episode Listen Later Jun 4, 2021 7:19


It's "In the News..." the only LIVE diabetes newscast! Give us five minutes and we'll tell you about: ATTD begins - what tech studies will be released? New info for hospital visits with diabetes tech Could a CGM also measure ketones? Another milestone for Tidepool T1D driver in the Indy 500 Join Stacey live on Facebook each Wednesday at 4:30pm EDT https://www.facebook.com/diabetesconnections Episode Transcription below Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Get the App and listen to Diabetes Connections wherever you go! Click here for iPhone      Click here for Android   Hello and welcome to Diabetes Connections In the News! I’m so glad you’re here! I’m Stacey Simms and each week I’ll share the top diabetes stories and headlines of the past seven days.  Whether you’re joining me live on Facebook or watching or listening after, I’m here to get you up to speed quickly on what’s happening with diabetes technology, research, and a few fun stories from our community. Since these are headlines and summaries, as always, you’ll find all the sources and links in the Facebook comments and in the show notes at d-c dot com. XX In the News is brought to you by Inside the Breakthrough. A new history of science podcast full of “Did You Know Stuff” XX here’s what’s In The News this week… First, the annual A-T-T-D conference is going on right now. That’s the Advanced Technologies and Treatments for Diabetes Conference. As it just started, we’re probably going to get a lot more info from the tech companies in the next few days. Stay tuned on social for big breakthroughs and announcements and we’ll wrap it up here next week. XX   Good News if you need to be in the hospital for some reason! The American Academy of Clinical Endocrinology has new guidelines that cover use of continuous glucose monitors, insulin pumps, connected pens, automated insulin delivery systems, telemedicine technologies, and smartphone apps. They also address safety considerations and special situations such as hospitalization. That’s really important because until now there has been NO official recommendation about letting patients handle diabetes management while in the hospital. New AACE guidelines https://www.medscape.com/viewarticle/952127 XX Could a CGM also continuously measure Ketones? JDRF is supporting projects looking to develop that kind of device. Here’s what they say in their request for letters of intent: Diabetic ketoacidosis (DKA) is a dangerous acute complication of T1D that is insufficiently addressed or even sometimes exacerbated by current therapeutic options. To fill this gap, JDRF invites applications to develop continuous ketone monitor or C-K-M functionality in continuous glucose monitor (CGM) devices. As I said, this is a request so we’re at the very beginning of this but WOW… that would sure beat peeing on a stick. CGM and Ketone Monitor https://grantcenter.jdrf.org/rfa/development-of-cgms-with-continuous-ketone-monitoring-functionality-for-dka-prevention-in-t1d/ XX   Follow up from last week – an FDA advisory committee gave the go ahead for the first drug shown to prevent type 1 diabetes. Teplizumab will now go to the full FDA and could be approved in early July. Teplizumab isn’t something you do at home.. it’s injections given over two weeks in an outpatient setting. The FDA doesn’t automatically follow the advisory committee recommendations and may ask for more info or research. We’ll keep following. Teplizumab follow up https://www.healthline.com/diabetesmine/teplizumab-new-drug-to-prevent-type-1-diabetes XX A new National Institutes of Health study aims to improve gestational diabetes screening and diagnosis by better understanding blood glucose levels throughout pregnancy During pregnancy there are changes in glucose metabolism but the details of these changes are unknown. The Glycemic Observation and Metabolic Outcomes in Mothers and Offspring study, or GO MOMs – will use CGMs to study more than 2000 women in their first trimester. This is a follow up study to HAPO – which isn’t quite as fun a name.. which looked at high blood sugar during pregnancy. Gestational diabetes BG study https://www.nih.gov/news-events/news-releases/nih-launches-study-determine-best-time-gestational-diabetes-screening XX Tidepool adds Control IQ to their long list of viewable data. If you use Tandem’s t:slim X2 pump with Control-IQ™ technology, you can now view all of your data, including all of the unique hybrid closed loop events in your Tidepool account. Tidepool is awaiting FDA approval on their own Loop system and they also launched a unique – and in my opinion  - much needed period project to start tracking how menstrual cycles affect blood sugar in in people with diabetes. https://www.tidepool.org/blog/tandem-control-iq-technology-and-tidepool-officially-supported Do you have a diabetes tattoo? News on who’s looking for it coming up but first.. quick break – want to tell you about one of our great sponsors who helps make Diabetes Connections possible. Inside the Breakthrough is a podcast that mixes historical wisdom with modern insight – it’s a science show that’s also entertaining. I love it. The latest episode talks about scientists who knew they were onto something but needed to see things with their own eyes. How actually seeing something like a Kraken? Makes a huge difference. It also meant a name change for what some thought had only been a myth. And this actually relates to diabetes! Listen to Inside the Breakthrough wherever you listen to podcasts.. Back to the news… Indy driver Conor Daly led the most laps in the recent Indy 500 but another car’s crash took him out of the race. Daly lives with type 1 – he was diagnosed at age 14. Another driver left his pit before the 4th tire was secure – when it rocketed around the track, it crashed into Daly’s car. He wasn’t hurt but it took him out of the lead. Conor drives the No 20 Mannkind Chevrolet – the makers of Affezza are his sponsor. https://www.indystar.com/story/sports/motor/2021/05/30/conor-daly-finishes-thirteeth-indy-500-after-tire-hits-car/5038239001/ XX From this week’s podcast episode! If you have a diabetes tattoo Banting House wants to see it! I spoke to the curator of the museum, know as the birthplace of insulin – it’s where Dr. Frederick Banting woke up with the idea that led to that great discovery. They are starting an exhibit “of ink and insulin” and they want to see your diabetes related tattoos. Of course, that link – and all the others in the Facebook comments and in the show notes at d-c dot com https://bit.ly/DiabetesCxns383 https://bantinghousenhs.ca/2020/01/16/of-ink-and-insulin/   That’s Diabetes Connections – In the News.  If you like it, share it. And feel free to send me your news tips. Stacey @ diabetes dash connections dot com. Please join me wherever you get podcasts for our next episode -Tuesday – you’ll hear from college students ready to graduate or already there. What they want young adults -and their parents – to keep in mind. Thanks and I’ll see you then!

Diabetes Connections with Stacey Simms Type 1 Diabetes
In the News: Your New Weekly Diabetes News Digest

Diabetes Connections with Stacey Simms Type 1 Diabetes

Play Episode Listen Later May 6, 2021 8:41


New information about kids with type 1 and COVID, a possible link between pollution and type 2, a look at Dexcom's latest earnings call and a lot more. We're trying something new for the next few weeks! Join Stacey live every Wednesday on Facebook for the top diabetes news and headlines or listen back via the podcast or on other social outlets. Full transcription and links/sources below. Watch the replay on our Facebook page or YouTube Channel Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Get the App and listen to Diabetes Connections wherever you go! Click here for iPhone      Click here for Android   Podcast intro: Hi all! This episode is very different. Instead of a classic episode, I wanted to try something new. What you’re about to hear first aired live on our FB page. Join me every Wednesday this month at 4:30pm eastern for DC the news! -- Hi, I’m Stacey Simms, the host of what’s usually a weekly podcast providing info & inspiration for people with diabetes with a focus on people who use insulin. I’m trying something new. A short newscast full of the top diabetes news of the past week. And that’s all types of diabetes. We’ll debut here on FB Live and then share on other outlets, including the podcast. The goal here is to get you up to speed – quickly – with good info. And let’s not forget.. Diabetes Connections The News is brought to you by Inside the Breakthrough. A new history of science podcast full of “Did You Know Stuff” Now..  let’s start! In The News… XX The majority of children with type 1 who tested positive for COVID.. did just fine. According to the very first report about this, from Barbara Davis Center, 77% of children with type 1 who had COVID were cared for at home, without complications. The children who were hospitalized were all diagnosed with diabetic ketoacidosis and the greatest risk for adverse outcomes was an A1C over 9. Fewer than 2% of all these cases required any respiratory support, and no deaths were recorded. Kids with T1D and covid fared well: https://www.medscape.com/viewarticle/950277 XX Another study about kids and covid.. The incidence of severe diabetic ketoacidosis among children presenting with new-onset type 1 diabetes doubled during the pandemic period compared with 2019, according to data published in Pediatric Diabetes. This research comes clinics in Canada from March to August 2020 and compared to the same period in 2019. The number of children diagnosed with T1D was similar but the frequency of DKA went from 45% to 68%. What they called severe DKA went from 13% to 27%. Speculation here is that fear of COVID kept people out of the doctor’s office until it was absolutely necessary, but these researchers say more education is needed around DKA even after the COVID pandemic ends. More severe DKA in kids during covid: https://www.healio.com/news/endocrinology/20210422/severe-dka-at-type-1-diabetes-diagnosis-doubles-during-pandemic XX Hat tip to chris Wilson for this.. Dexcom had it’s first quarter earnings call last week. Still expecting G7 to launch in Europe ahead of the US, with US launch towards the end of the year. We’ll find out more details about the G7 at ATTD conference this summer. That’s the advanced technologies and treatments for diabetes conference. Chief Operating Officer Quentin Blackford also reports that quote, “we rolled out an update to the G6 algorithm in the first quarter. We believe this update will drive further reductions to times in which data is temporarily unavailable And I've seen excellent results from the initial launch of this updated algorithm in Canada in 2020.” I’ve talked to Dexcom a few times about how they can make changes to the transmitters and sensors that don’t require regulatory approval – no announcement they just roll them out. Looks like this was one of these. https://www.fool.com/earnings/call-transcripts/2021/04/29/dexcom-inc-dxcm-q1-2021-earnings-call-transcript/ XX Looking at type 2.. A new study suggests that people exposed long-term to certain air pollutants may have a higher risk of diabetes. This was part of the ongoing Jackson Heart Study which looks at African American patients in Mississippi. The study included more than 5000 people ages 21 to 94 in the Tri-County Jackson area.. where traffic is the major source of ambient air pollution. Levels of diabetes and of pollution exposure were assessed 1 and 3 years prior to visits 1 and 2. They reported a diabetes prevalence of 21.8% at visit 1 and 33.2.% at visit 2. Furthermore, 12.5% of those without diabetes at visit 1 developed it by the second visit. Theses researchers say the results provide some evidence that the exposure is linked to diabetes. Apparently there are very few studies of environmental pollution risk factors in communities of color – these researchers say more follow up is needed. Air pollutants and type 2 diabetes: https://www.hcplive.com/view/air-pollutants-associated-diabetes-prevalence -- Quick note about gestational diabetes. Turns out few women who meet the criteria for early gestational diabetes screening receive it. This study was only done at one location, but the authors say it’s indicative of a greater problem. Only 12% of women who met the American College of Obstetricians and Gynecologists’ criteria for early gestational diabetes screening actually received it at a New York hospital. It’s recommended that all pregnant women be screened for gestational diabetes (GDM) at 24 to 28 weeks. Nearly one-fifth of the women who met the criteria for early screening but were not screened were ultimately diagnosed with gestational diabetes further along in their pregnancy. https://www.healio.com/news/primary-care/20210501/few-women-who-meet-criteria-for-early-gestational-diabetes-screening-receive-it XX Quick break – want to tell you about one of our great sponsors who helps make Diabetes Connections possible. Inside the Breakthrough explores the idea of a “Eureka” moment. It’s historical wisdom mixed with modern insight – a little bit history show, little bit science show. The latest episode tells the story of Dr. Banting and the discovery of insulin. Every week is a different story – they’ve talked about snake oil and leaded gasoline & crime – but this week has info about the discovery of insulin that I’d never heard.. Banting had to sell his car to get money to buy dogfood. And of course, there’s scientific info as well. Listen to Inside the Breakthrough wherever you listen to podcasts.. XX Back to the news.. one of the pioneers of diabetes technology passed away this week. Helen Murray Free co-developed the dip-and-read diabetes test, a paper strip that detected glucose in urine. She died on Saturday at the age of 98.  Before the invention of the dip-and-read test in 1956, technicians added chemicals to urine and then heated the mixture over a Bunsen burner. The test was inconvenient, and, because it could not distinguish glucose from other sugars, results were not very precise. Ms. Free and her husband figured out how get strips of filter paper to turn blue when glucose was present. The test made it easier for clinicians to diagnose diabetes and cleared the way for home test kits, which enabled patients to monitor glucose on their own. https://www.nytimes.com/2021/05/03/science/helen-murray-free-dead.html And finally, big book launch this week – Chris Ruden is out with The Upper Hand: Leveraging limitations to turn adversity into advantage. Chris is one of our favorite guests – he’s been on the podcast a couple of times. Chris was born with 2 fingers on his left hand and a shorter left arm. He was diagnosed with type 1 at age 19. He’s a champion power lifter – he’s been on the Titan Games and got a big hug from The Rock – and he’s out with a new book. Again it’s called The Upper Hand.. Congrats Chris! XX That’s our first Diabetes Connections – The News. I’m going to do this for about a month and see what the response is. If you like it, share it. And feel free to send me your news tips. Stacey @ diabetes dash connections dot com. Please join me wherever you get podcasts for our next episode -Tuesday – we’re talking to the folks from Zealand Pharmacy about the newest shelf ready emergency glucagon -Zegalogue Thanks and I’ll see you then!

Diabetes Knowledge in Practice Podcast
Self-directed titration with insulin: which algorithms are suitable?

Diabetes Knowledge in Practice Podcast

Play Episode Listen Later Sep 1, 2020 13:24


International guidelines recommend patient self-directed titration of insulin where initiating a basal regimen. However, these same guidelines do not appear to provide any clear direction of which algorithm should be used, other than it be “evidence-based”. With this in mind, how should we select between algorithms to offer our patients? Join us for a quick summary of three example algorithms before discussing optimal approaches with Dr Ronald Goldenberg from LMC Diabetes & Endocrinology in Thornhill, Canada. References: Davies MJ,e t al. Diabetes Care. 2018; 41(12): 2669-2701 ADA. Diabetes Care 2020; 43(Suppl 1): S1-S2 Davies M, et al. Diabetes Care. 2005; 28(6):1282-1288 Meneghini L, et al. Diabetes Obes Metab. 2007; 9(6):902-13 Yale JF, et al. Poster presented at: ATTD 2017, 15-18 February, Paris France. This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.

Stein Monogastric Nutrition Lab Podcast
Digestibility of energy and dietary fiber by growing pigs in corn- or sorghum-based diets without or with microbial enzymes

Stein Monogastric Nutrition Lab Podcast

Play Episode Listen Later Aug 20, 2020 10:45


Dr. Maryane Oliveira, a postdoctoral research associate in the Stein Monogastric Nutrition Lab, presents the results of a study in which xylanase and cellulase were added to corn- and sorghum-based diets fed to growing pigs to determine their effects on fiber digestibility, ATTD of gross energy, and metabolizable energy. Adapted from a presentation at the 2020 ASAS Midwestern Section meeting, Omaha, NE, March 2-4.

Aligned to the Divine Podcast
ATTD 6: Forgiveness is a form of self- love: Aries 2020 New Moon #throwback

Aligned to the Divine Podcast

Play Episode Listen Later Jul 15, 2020 14:20


Diabetes Connections with Stacey Simms Type 1 Diabetes
Minisode #9: Hey Doc! Listen up!

Diabetes Connections with Stacey Simms Type 1 Diabetes

Play Episode Listen Later Feb 27, 2020 16:19


Have you ever had a doctor give you a "wake-up call?" or try a "scared straight" tactic? These techniques - and a lot more - blew up on Twitter recently. Stacey noticed that it also seemed that the doctors andhealth care providers who weighed in weren't interested in listening to diabetes advocates online. What's the disconnect all about? Full transcript below Check out Stacey's new book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Get the App and listen to Diabetes Connections wherever you go! Click here for iPhone      Click here for Android Episode Transcription:  Stacey Simms  0:00 This episode of Diabetes Connections is brought to you by The World's Worst Diabetes Mom: Real Life Stories of Parenting a Child With Type 1 Diabetes available on Amazon as a paperback ebook and audiobook at Diabetes Connections.com.   Announcer  0:15 This is Diabetes Connections with Stacey Simms.   Stacey Simms  0:26 Welcome. This is one of our mini episodes, shorter episodes that I put together starting at the beginning of this year, just when I have something to say, news to share or anything that doesn't fit in the traditional longer format interview show that we do every week that drops on Tuesdays. I am your host, Stacey Simms, and I want to talk to you today about well, I really want to talk to your doctors about something, but we'll get to why and maybe how to share with them. I want to talk to you about what are doctors think of diabetes, and I don't really mean our endocrinologists Just to hopefully know what they're talking about and stay up to date. I mean, the other doctors that we see or we bring our children to pediatricians, the doctors, the dentists, you know what I mean, right? There seems to be this disconnect between what the diabetes online community which doesn't speak in one voice, I get it. But what we have learned over the years and what we talk about all the time, in terms of there's a hashtag language matters, right? There's this disconnect between what we as patients want, which is no blame and shame. Work with me, help me with resources, give me the information, let me make my decisions. And the physicians who many many, many times want to scare patients straight, you know, we're gonna give them a wake up call. We're going to show them how bad they're doing and that will make them do better. And this disconnect played out on Twitter recently and I want to share with you how it went and then I would ultimately was shared at a medical conference. Before I jumped right in though I do want to Say with those doctors who are you know, in the scare em  straight kind of school, I really do think the intentions there are good. I don't know any doctor who wants their patient to walk around with a 14 A1C, you know who obviously isn't feeling well and is going to be in poor health. I don't think any doctor wants that. The question is, why don't some doctors listen to their patients more? Why don't they seem to believe us when we tell them what we think works and doesn't work. So that's my perspective. today. Let's go through what happened. There's a guy on Twitter. His name on Twitter is @DGlaucomflecken. He says he's an ophthalmologist, a comedian, and a speaker. On February 17. He tweeted, “Want to know why diabetic eye exams are so important. I can take a 28 year old with an A1C of 14, show her a picture of a normal retina, then a picture of her diseased retina. Then a picture of what her retina could look like in 10 years with an A1C of 14. Very effective wake up call.”  And he posted the pictures that he had just talked about now. Kind of an innocuous tweet a couple of years ago, I probably wouldn't have thought anything of it. But and I was not alone here. There were some telling language in this that made me want to speak up. I'm going to link this up if you want to go through the Twitter thread. It is ginormous because a lot of people chimed in as you can imagine. I'm going to read a few tweets here. I'll just read first names from the people who tweeted this out. So these are the advocates who tweeted back Megan wrote, “As someone who works in eye casualty for a while and has type 1 diabetes. I have heard doctors have similar conversations. I then also seen patients walk away upset and distressed. Living with diabetes can be filled with anxiety. I find it best not to feel that scare tactics aren't always the best understanding and empathy for diseases hard to manage may be better.” Melinda wrote, “Did you ask her if she could afford her insulin and supplies? If she had a support network to encourage her or did you just decide to be Dr. Judgy Pants?” Melissa wrote, “Do you know if she went to her car and cried from helplessness like I used to after I exams with an ophthalmologist who had This kind of bedside manner? It took some time to find a doctor who could help me create a plan instead of send me off alone and frightened.” And then Mike wrote, “This mentality scared me into doing something better briefly as a teen. Soon enough, it led to hopelessness and years worth of higher A1Cs until love, actual good doctors and peer support inspired me to change how I lived” I wrote “Curious if there are any long term studies showing this is effective, other than the patient saying, Wow, that's a wake up call. What is it like for them? 10 years down the road? Did it help hurt make no difference?” And I actually wrote “not being sarcastic, genuine question” because you know, Twitter, but then the ophthalmologist chimed in back. And during all the time these advocates are saying these things, other doctors and other people are telling us how wrong we are. So the original ophthalmologist chimes in with, “I'm just showing people their own body part. I've never had a patient get upset with me for showing them pictures. I have taken up their own body part. I don't need a study to convince me to keep doing that.” Another doctor said “Patients Like pictures. We do the same with coronary angiograms. In cardiac patients, a picture's worth 1000 words, also puts in their minds the idea of the now and the potential future, good practice.” Another person a medical resident wrote, “I like it, it's hard to convince some patients without symptoms that keeping an A1C down to an arbitrary number is worth the effort of diet, exercise and expensive meds. This could help motivate many patients.” And then he writes “Also, it's not the author's job, the ophthalmologist job to make sure the patient has all of the resources needed to adequately treat the patient's diabetes during their brief eye exam. That's our jobs as PCPs.” So that's what he's going to be or may be already is I can't really tell from his Twitter bio primary care physician. Okay, so, literally, this went on for days, I kept getting notifications, because I kept chiming in, like, Are there studies like, oh, let's talk about this, you know, and, as you can imagine, it got pretty nasty sometimes. I mean, there's jerks in every Twitter thread on every side, so we're not going to talk about that. We're going to talk about the discussion and the disconnect because this is that fascinating. Most of the doctors really believe this is a good thing, I'm so glad that that primary care physician chimed in and said, “well, it's really not your job as an ophthalmologist to give them any resources or do more with them.” And this original doctor kept chiming in and saying, “No, I really do try to support patients.” It was just one tweet, you know, we don't know what he's really doing. So maybe he is, you know, talking to them more. What about your experience? In my experience with those other doctors, right, not the endocrinologist, the eye doctor, the dentist, even the pediatrician with Benny, they have no idea what diabetes takes. That's okay. It's not their specialty. I don't mind that. They don't know. I mind when they try to tell us more than they know. Right? Like, I had an eye doctor once Tell me, Benny was not in the room, he asked, “how long has he been diagnosed?” 12 years. I think at that time. “Well, you know, 20 years is when the complication starts showing up in the eyes.” And I actually said out loud because I'm a pain in the ass patient. And I said, Really? What was the last time you actually read anything in a medical book about diabetes? I tried to be nice, I said it kind of nicer than that. But it's it really, when did you learn about type 1 diabetes? And he said in medical school, and I said, and when was that, right 25 years ago? And really, when were those studies done? Right? If you're looking at a study from 25 years ago, that study probably followed people living with diabetes who had been diagnosed at least 10, if not 20 years before that. So your data is kind of outdated. And we know if you're a longtime listener of the show, you know, from studies like the EDIC trial, and many others, that eye complications, along with many other complications are way down and almost non existent for people with diabetes, who have access to good care and insulin. I mean, we know there's a whole other world out there, but we know these complications when care is given our way down. And whenever I talk about complications, I always want to say complications can happen even with the best care with diabetes. I mean, look at life - complications can happen with anything. So we try to do the best. We can see just other factors, you know, genetics, environmental, what have you. But with eyes in particular, I've talked to two endocrinologists in the past year, who say when they see a patient with any kind of eye issue under the age of 40, with Type 1 diabetes, they call everybody who's nearby, because they never see it. They want everybody to come in and identify it and look at it and see what the poor patient, but see what it really is all about, because they never see it anymore. So my little conversation with that eye doctor, hopefully made him rethink a little bit about how he talks to other people with diabetes. I've had the same conversation with my pediatricians when I feel like educating because sometimes it is absolutely exhausting. And I had to back away from the Twitter thread because of that, that it is exhausting to keep educating and educating. You don't know everything about type 1 diabetes, you're not a specialist. Thank you for pointing this out. But what can we do about it? What's the point? Why would you say you're going to be in trouble? I'm going to give you a wake up call. I'm going to scare you straight. Why would you say all those things Thinking the outcome is going to be positive? If you're aware of a study that talks about these things, and I was pilloried on Twitter for suggesting there could be a study, what would the control group look like? people who never get good health information, people who are never shown their bad eyes, or that they're going to lose a limb or blah, blah, blah, right? No, look, I don't create scientific studies. But you don't have to be a genius here. But why couldn't you something really short, that just gives you a taste of what we're talking about here? Do a six month study, right? Pick an age group to a six month study your 25 year olds with Type 1 diabetes, everybody gets the same exams, but your feedback is - you're doing terrible. You have to be nervous. We're scaring you straight, kiddo. It's a wake up call. Now go get better. And the other one is, Hey, I really feel like we could do more together. Well, how can I support you? What are the challenges you're seeing that are creating these issues with Type 1 diabetes, there may not be anything I can do to help but I understand that you're probably doing the best you can because type one is really difficult. And then the other one, the third part of the study would People who are told here are your test results. See you next, right with no emotional kind of feedback. Why couldn't you do a quick study of that and see what happens in just six months? My guess is you would see really interesting results. So better minds than me, thank goodness picked up on this and actually put it in a presentation at ATTD, at the international conference for advanced technologies and treatments for diabetes. This is the conference that I just talked to Kevin Sayer. That episode just aired a couple days ago. This is where he was in Madrid, Spain. So this is a huge international conference and this Twitter thread made it to a presentation, which shocked me. What shouldn't have shocked me is who was doing the presentation. This was the hashtag talk about complications presentation by Renza Scibilia and grumpy pumper Chris, who we've had them both on the show separately to talk about this and other issues. But this talk about complications slide that made its way to the presentation showed the original a tweet from the doctor, the ophthalmologist comedian, and they actually blacked out his name, which I didn't do here, because Twitter is public. And they showed the original tweet, you know, very effective wake up call. And then they put another tweet next to it. And I think that this is a hope that physicians might consider saying this instead. So let me read you the original tweet again. And then the one that they suggest. So the original tweet, “Why are diabetic eye exams are so important? I can take a 28 year old with an A1C of 14 show her a  picture of a normal retina, then a picture of her diseased retina then a picture of what her retina could look like in 10 years with an A1C of 14. Very effective wake up call.” Here's an alternative to saying that “Diabetes is really tough, and you're managing as you can right now. Thank you for coming to see me eye screening is really important. We know having a higher A1C increases the risk of diabetes related conditions. Let's work together to try to reduce the risks.” Now I know some of you and maybe hopefully if you got your physician or not Doctor or dentist or somebody else to listen to this episode, it might sound very, you know, Kumbaya and woo woo. And, you know, let's work together. But I'm telling you, as the mom of a kid with type one, as a person who sees doctors for her own conditions, it is so much more helpful to hear this than to hear the other scary, effective wake up call. I mean, you know, when I go to my doctor, and I say, I'm really upset, I've been trying hard and gaining weight, you know, what I don't want to hear is “You're really fat. And we know that being obese can help lead to health complications, and higher increase of cancer. Because you know, you really want to watch out what happens, you have this risk and your family and blah, blah, blah. So just stop eating desserts.” What would be really helpful is, “Yeah, boy, it's really tough. I can see that your whole life, you've been a healthy weight. You're an active person who knows how to eat well. What's changed in your life in the last couple of years? How old are you? What is your metabolism doing? Let's sit down and talk about how things are changing maybe so that you can find a plan that might help you change” I mean, I just came up with that at the spur the moment, but it's so much different to here. Let me help you. And let's figure out what you can do to make this better rather than let me blame you and shame you and scare you. A lot of people tune that out. And if they're scared, they don't want to do anything to make it better because they lose hope. I really hope that some healthcare professionals who saw this on Twitter took a moment to stop and think about it. I know a lot of them responded. And remember kind of insulting frankly, calling the diabetes advocates, trolls and one person called the bats. I don't know if that's a UK thing, or I don't know what that was all about. And there were some people who got kind of nasty, as I said earlier, but I really hope that people who saw this conversation, maybe had a different conversation with the next patient that came into their office, maybe a person with diabetes, who saw the conversation had the words now to tell one of their health care providers. Look, this isn't helping me. I need you to speak to me in this way. Which is really, really hard to do. I will say before I let you go here that a lot of the physicians piped in with Well, my patients never react poorly when I give them this news, they all seem to appreciate it. Do the doctors not know that we talk to them differently than other people? Do doctors not know that some people like get dressed up to go to the doctor will really make sure that they are well groomed. I mean, it sounds silly, but you know exactly what I'm talking about. Right? doctors don't realize that we go to our cars. And as Melissa said, in that tweet, sometimes we cry, we call the friend and say you won't believe what happened to me. Or some people will tell a nurse things that they won't tell a doctor or they'll tell the front receptionist and they'll get the anger and so the doctor, people don't tell their doctor unless you're me and you're a pain in the butt. Very few people tell their doctor, hey, you're wrong. Or I don't like this. Or even Can we try something different? People don't talk back to doctors. And the fact that they don't know this… Come on, guys. You got to be better. You got to think about it. What do you think my way off base here? Were you part of that? Twitter chat, did it make you mad? Did it make you think? Let me know. You can always email me Stacey at Diabetes Connections. com. I'll put this in our Facebook group as well Diabetes Connections of the group on Facebook. I'd love to keep the conversation going. If you're a physician who has listened to this long oh my gosh, thank you so much. I cannot tell you how much we appreciate it when you take a moment to consider the other side of the stethoscope for lack of a better word. Let's keep this conversation going. Of course, if you think I'm wrong, I am the world's worst diabetes mom, I can live with that. And you can find out much more at the website diabetes dash connections.com. Please subscribe to the show on any podcast app or just keep listening through social media or however you found us. We appreciate that we're not going to tell you where to listen. We just hope you keep on tuning in. I'm Stacey Simms, and I'll see you back here next week.   Unknown Speaker  15:57 Diabetes Connections is a production of social Stacey Simms media All rights reserved all wrongs avenged   Transcribed by https://otter.ai

Diabetes Austria
22 -ATTD 2020 - Prof. Dr. Kinga Howorka

Diabetes Austria

Play Episode Listen Later Feb 25, 2020 20:25


Ihr Fazit zum Kongress und über die immer wichtiger werdenden Schulungen für Patienten

Diabetes Connections with Stacey Simms Type 1 Diabetes
Dexcom CEO Kevin Sayer Answers Your Questions

Diabetes Connections with Stacey Simms Type 1 Diabetes

Play Episode Listen Later Feb 25, 2020 43:51


This week, catching up with Dexcom CEO Kevin Sayer – overseas at the ATTD conference. We talk about everything from a G7 update, new partnerships, in-app notifications and those sensors that you’ve probably heard about getting stuck. We also talk about competition, customer service and a lot more. Join the Diabetes Connections Facebook Group! In Tell Me Something Good, a Miss America contestant with T1D has pretty stellar week – and it has nothing to do with her crown and sash.. this is about engineering . Check out Stacey's new book: The World's Worst Diabetes Mom! This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Get the App and listen to Diabetes Connections wherever you go! Click here for iPhone      Click here for Android Episode transcription (we're in beta so please excuse grammar, spelling, punctuation and the fact that AI can't figure out Dexcom speak) Stacey Simms 0:00 Diabetes Connections is brought to you by One Drop created for people with diabetes by people who have diabetes by Real Good Foods, real food, you feel good about eating, and by Dexcom take control of your diabetes and live life to the fullest with Dexcom. Announcer 0:21 This is Diabetes Connections with Stacey Simms. Stacey Simms 0:26 This week, catching up with Dexcom CEO Kevin Sarah overseas at a big diabetes Technology Conference. We talk about everything from the g7 new partnerships in app notifications. And those stuck sensors that you've probably heard about or seen on social media. Kevin Sayer 0:45 There's a freak out factor but Let's face it, if that's your last sensor, that's not fair. And that's not right. So we noted it, we've seen it, we've read it. We've done everything we can to mitigate it. I'm very comfortable we’ll see this come down. Stacey Simms 0:57 We also talk about upcoming CGM Competition, customer service, direct to Apple Watch and a lot more. in Tell me something good on Miss America contestant with Type 1 diabetes has a pretty stellar week and it has nothing to do with her crown and sash. This is about engineering. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your healthcare provider. Welcome to another week of Diabetes Connections. I am your host Stacey Simms, we aim to educate and inspire about type 1 diabetes by sharing stories of connection. My son was diagnosed with type one, just before he turned two. That was more than 13 years ago. My husband lives with type two diabetes. I do not have diabetes. I have a background in broadcasting and local radio and TV news. And that's how you get the podcast. longtime listeners know what the show is all about. letting some new people know because let's face it anytime we talked to dexcom or talk about anything New technology, we get a lot of new listeners. So welcome! If you've come for that, I hope you stick around and go through our almost 300 past episodes. Now, you can find everything at Diabetes Connections. com, we have a very robust search, there's the regular old search box on the upper right hand side. Or if you click on the episode page, there is a way to sort them by category. So if you want to see all the technology episodes are all the ones with athletes are all the ones about family or advocacy, you can sort them that way as well. Before we talk to Kevin Sayer, it is important to point out that as you heard the very top Dexcom is a sponsor of this show, and has been for a few years now. Our agreement means I talk about them in a commercial, which you will hear later on the show. But it doesn't mean that I don't get to ask hard questions. I really try to serve you as you listen, I try to serve you first. And if I'm not doing that this show doesn't work ethically. It's really important to disclose these things. And I always get upset when other either podcasters or bloggers or speakers don't do that. If you're a longtime listener, you understand how it works around here. Hopefully, I am doing a good job of serving you. But just to be clear, the advertisers in the show pay for the advertisement. And I believe in them, and I'm glad they're here. But they do not tell me what to say, in the show anywhere else on social media, or when I write a blog, that sort of thing. It's not that kind of relationship. So we're talking to Kevin coming up in just a couple of minutes asking your questions. I took a whole bunch of them from the Facebook group. We do have a Facebook group, it is Diabetes Connections, the group, very original, but very easy to find that way I thought, and that's really the best way if you want to ask these newsmakers questions I usually ask in the group and you can always contact me that way. That's coming up in just a minute. But first Diabetes Connections is brought to you by another sponsor, One Drop. It is so nice to find a diabetes product that Not only does what you need, but also fits in perfectly with your life. One Drop is that is the sleekest looking and most modern meter My family has ever used. And it's not just about their modern meter setup. You can also send your readings to the mobile app automatically and review your data anytime, instantly share blood glucose reports with your healthcare team. It also works with your Dexcom Fitbit or your Apple Watch. Not to mention they're awesome test strips subscription plans, take as many test strips as you need, and they'll deliver them to your door. One Drop diabetes care delivered, learn more, go to Diabetes Connections calm and click on the One Drop logo. My guest this week is Dexcom CEO Kevin Sayer. He is joining us from the International Conference on Advanced Technologies and Treatments for diabetes, which this year is in Madrid. So as we're talking to Spain here, please pardon any glitches or weird phone sounds that might pop up but hopefully all will go away. Kevin, thank you so much for joining me. I appreciate it. Kevin Sayer 5:02 Oh, thank you, Stacey. It's good to be back again. Stacey Simms 5:05 All right, let's start with the news that has already come out of the conference. And that is this official partnership with Insulet. With Omnipod. Can you start by talking a little bit about? And I'll be honest with you, I'm a little confused. I they're already in clinical trials for Horizon. I thought this agreement was a done deal. Tell us about the agreement with Insulet. Kevin Sayer 5:23 Actually, we've been working with Insulet since 2007. This is a long time relationship. And most of our work in the past was then under the form of a development agreement to jointly develop products together. The announcement this week is the culmination of all that development work over time to basically say, look, we've entered into an agreement whereby we know how we're going to commercialize our joint systems. And also, as we have entered into these development agreements with our partners, we typically do it one generation of technology at a time, we made the g7 system available to the Insulet team as well. So once they get a rising launch with G6, as the G7 system gets ready to go, it will be will be able to migrate over to that system as well. So that that was the purpose of this announcement and the other. You know, the other reason for it, there is so much going on in the interoperability world right now. We index coms as well, it's important that everybody knows that we have these relationships. And this relationship is very close and near and dear to us. So we therefore thought the announcement was good on something we have been working on for a very long time. Stacey Simms 6:29 When we look at interoperability, you've mentioned already G6, G7. Can you just take a step back and give us a little bit of an update on that so Insulet will go with their horizon, which is not out yet. That'll be g six and G seven tandem with control IQ also g six mg seven Kevin Sayer 6:50 Tandem has access to G6 right now. We've not yet signed a G7 agreement with them, but we'd expect to do that and then they're very near future. We've also signed a relationship with Lily and their connected pens and their platforms, whereby they'll have access to G six and G seven as well. We have several other smaller relationships with some of the smaller pump companies or others where they have to six, access not a lot of g7. At this point in time, we have to look at that strategy over time and decide what approach we're going to take with partners. The interoperability world creates some very interesting business scenarios, which I wish I knew the answer to all of that, but it ranges anywhere from let's say, one person and go or two people and just work with them to maybe a few or just open it up to everybody. And I think it evolves over time. For us right now. We think it's important that we support certainly as many as we can, but offer even a heightened level of support to those who are going to have commercial offerings in the near future as speaking towards Tandem and Insulet. In particular, the control IQ uses g six and we read certainly very good things about that is that since we've been out there. And so we'll work with them all. This is going to evolve over time. All the answers are available. Sure. Stacey Simms 8:07 Okay, so let's talk about control IQ quickly, because that's been in the news quite a lot lately. We just started it about three to four weeks ago. It's been working very well for my son, but Dexcom owns the algorithm, but used to be called or maybe still is type zero. Kevin Sayer 8:23 So let me give a little clarity on the fundamental or the underlying science and the calculations behind the algorithm are in fact, developed a type zero and owned by Dexcom. Tandem has filed that as their controller. They have done some user experiences some modifications as to how it is integrate into their pump, but the fundamental algorithm is owned by Dexcom. And type zero. That's correct. So the sensor in the algorithm driving it are Dexcom properties. Stacey Simms 8:49 This is a little bit more esoteric than I expected to get in so quickly here, but what's it like being in the algorithm business and Do you have plans to perhaps get some other algorithms in Your tool kit, if you're like us, not the only one out there Kevin Sayer 9:02 know when we've looked at those, and we love our team in Charlottesville, we have some decisions to make there too. So what we're going to do long term with the algorithm and how available we're going to make it, it is a great business opportunity is a great skill set for us to have as well. With that team in Virginia, we've learned a lot about our sensor, their opportunities to take the science has been developed for automated insulin delivery and apply it to decision support for those who really don't want to use a pump all the time that we could possibly provide some good decisions along the way that would help them better manage their diabetes in the manner that they want to. I think there are a lot of opportunities to do that here. What we're going to let it play out, we're still early on in in that one. They're certainly next generation algorithm to come after they control iq version of it, which is kind of a step up or there's even less user interaction where you possibly won't have to announce all the meals and Everything that will be a little more aggressive on treatment and require a little less user interaction. And we got to figure out what our strategy is going to be to do that and how we're going to go with that. So we're kind of in the algorithm business, but sensors are still our biggest, you know, that's where we pay our bills, the most important thing for us, when we saw that asset was kind of available out there that we felt it was something that we just needed to control. And then we're thrilled with it. And quite frankly, it's worked out well for me, too, because they're right away from us in San Diego. And we can very much collaborate very quickly, since we have access to those scientists and they have access to us. Stacey Simms 10:39 So let's talk about the g7. We've talked about it before. Can you give us an update, what the features will be? What makes it different and the timeline? Kevin Sayer 10:49 Well, as we've talked, I'll start with the timeline, as we've said in our public statements, will be starting a typical study this year. Our hope is have a limited launch in 2020 The limited line for that have a significant impact on our financial results. So in the public world, we don't say a whole lot about the limited launch, we intend to do the full ride in 2021. And I don't have a perfect time frame yet, I will tell you, the mitigating factor will more than likely be our ability to scale it up. As you know, from your community. We learned a lot in 2019, about scale and all those lessons were not necessarily positive, the Dexcom. But they were good learnings. It was hard, we underestimated some things when we rolled to six out the way we did and I don't know that even if we delayed three or four months like to its original plan launch date, that we would have solved those problems because the demand for G six was so much higher than we anticipated. It would be you know, in the past, we could overcome 20% more demand than we have because we didn’t fill that many sensors. So yeah, if you’re manufacturing 2 million sensors. We can come up with another 200, 300 thousand, that's not a problem. But when you use the numbers we're at today. becomes a problem. So if anything, we learned anything from the big six launch, we are going to be prepared to scale g7 when we launch it, because when it comes, nobody's going back, just like nobody's going back to G five g six features of the product, as we've talked about before it much thinner, smaller profile, disposable electronics. So there's not a transmitter component anymore. There's no assembly of anything before you put it on, you literally take it out of the box, press the insertion device into your skin and hit the button and you're gone much smaller plastics profile. from an environmental perspective, patients will be glad to know that we get that comment frequently on our current system about all the plastics length of where we're shooting for an extended wear period. I have to tell you, we will balance the extended wear period against the accuracy and performance of the system with respect to iCGM standards. We know we have to have this as an iCGM to talk to these automated delivery systems and sometimes you make trades offs. Length of wear versus accuracy, as most people know, at some point in time, the longer you wear a sensors, the more difficult it is for to perform perfectly. One of the things that I often that isn't understood about g six, I can give the perfect example, these standards set by the FDA on iCGM are difficult. They're not simple to meet. And literally the way that g six algorithm works is if through our and our analytics, we look at the sensor signal and determine that that sensor is about to become less accurate than it should be, under iCGM rules, we turn it off. So there's a perceived lack of reliability from some of our patients on the sensor, when in fact that's not the case at all. We're turning it off intentionally. And that's very often associated with physiology. You know, people's bodies are different, and even sensor sessions can be different based on how much activity you have or where, the place you insert the sensor. So we're hoping for an extended To 15 day, where it certainly wouldn't be less than 10. We will go either way, but we need to make sure we meet the criteria. The sensor is much shorter than g six. So it will be a shorter sensor from our user experience so far and our preclinical work we've had nothing but great feedback on that. Stacey Simms 14:17 What does that mean? Is it a shorter wire or a shorter device, smaller, shorter wire Kevin Sayer 14:22 Shorter wire with the direct insert, not angle, but it is straight in but it's very, very short. Stacey Simms 14:33 More to come on the g7 and many other Dexcom issues. But first Diabetes Connections is brought to you by Real Good Foods, good foods, and their philosophy is all about keeping it real with food with community and with each other. And if you go on their website, you can find out so much more about the product real food, high protein, it's not about chemically made protein powders. This is about food, chicken cheese Right, low carb, grain free and zero added sugar. They keep adding products. We are big fans of the original pizza and the poppers but they've added a breakfast sandwiches with sausage or with bacon, cauliflower crust pizzas, chicken alfredo, other Italian entrees. They just keep adding more great stuff, find out more, go to Diabetes Connections calm and click on the Real Good Foods logo. Now back to my interview with Kevin and we were talking about the g7. You mentioned the the longer were balanced with their performance Do you expect the g7 to perform differently to perform I hate to say better but to use the criteria you were talking about with the iCGM? Do you expect fewer issues with either Physiology or the sensor sensing that something is wrong and then turning off. Kevin Sayer 15:57 That is our hope and our belief? We have learned So much from G six, as to what we can improve and make better It's been one of the scientists said to me the other day, he feels like he's working in a semiconductor factory. We're learning that much about sensors these days, as we're preparing for this setting to launch this product, we may not even be able to get all the things we've learned into the first version. But I think there'll be a couple of iterations whereby I know the extended wear will come and I know that that the reliability will be there. One of the things that we put around ourselves as a criteria is to significantly improve the reliability percentages. And we were experiencing on G six today, both on G six going forward and on g7. It just doesn't work. Patients have to return to the sensors, because they fall off or don't last long enough. We have to make that experience more consistent. So we're very focused on that. Not just with you seven, but with the six improvements as well. Stacey Simms 16:51 All right, this next one, I just have to get it out. Kevin, I feel like a broken record. But can we talk about direct to watch what's going on? I know there's been a lot of holdups but is that something that’s happening? Kevin Sayer 17:03 No, and we're working on it I appreciate you asking again, is technologically very difficult a Bluetooth protocols on the watch are not the same as the phone. And I go down to r&d and I asked the guys a question, every time I talk to you tell me what's going on. And it's not only difficult from the Bluetooth perspective, there's an experience perspective, it's also difficult with respect to the alerts Can we make it worse, audibly loud enough for by somebody can hear them? What happens when you take your watch and you put it on your charger and it's your primary displaying walk away, there's some where issues and some issues around the watch to create a little bit different experience and required a bit more fun on our part, and quite candidly, a lot more complex engineering. And we have done firmware updates to get us closer there. When we're done. We'll announce it. The other thing I would tell you is even if we weren't finished today, I wouldn't tell anybody I'm not trying to tell anybody till every transmitter in the field is was compatible because it will be different. version of the firmware on the transmitter. And while it was still be seamless on your iPhone or your Android phone, it will look the same if we announced direct to watch, and then we have a bunch of transmitters in the field that don't go director will watch, we're creating a tech support issue that will just again lead to patients being upset. So we're working on it, it's just a ways out and all these opportunities or engineering, things we have to get done are not just caused by Dexcom, either. There's Apple things that we just have to understand better. They work very closely with this. They're very helpful. It's just taking a lot of time. Sure. Stacey Simms 18:34 Well, thanks for the update on that. It's nice to know, you know, there's always a fear that these features may not get rolled out right. There's always a fear that and I know you know, this is the type one community that we see CGM makers and other technology companies looking at the the enormous type 2 market which has very different needs very different wants, and that we will be left behind so the watches I mean, it's a little bit dramatic to put it in that way. Looking at direct watch, but you understand what I'm talking about, right? Kevin Sayer 19:03 Yeah, I do. And I let me respond to that a little bit, please do. You're right. There are a lot more people with type two diabetes, type 1 diabetes, but there is nothing that we do for people with type 1 diabetes, that can't create a great experience for people with type two diabetes. I would argue that the good things we do for type one patients translate better over to type two then heading down a path with lesser accuracy, or lesser connectivity or fewer features. You're much smarter to make a product performance is superb level and then make the changes software related rather than then system related. And rather than sensor related, which is the way we're doing it now. Or you know, there was a big fear that g7 would be a type two product only hired that from a lot of patients because barely our partner been a great partner has been very much focused on type two where they're on duo, a managed diabetes management program, but that's not the case. We We will launch our g7 system with his ice ice jam label current plans are a legit person in the type one space. After that, even with G six, we can adapt the G six platform to a type two patient that has a different software experience. It doesn't detract at all from what we do for our core market. And where we sit today, the most important thing to do is to get a like if you get accuracy and performance and reliability and consistency, you can take that anywhere. And that meets our type one patients need and will also gives us the business flexibility that we need to go forward. But we're not going to do that if we were looking at something for another market. And I'm speaking way out in the future. today. It might be another platform that would measure multiple analyze that wouldn't have ice jam accuracy for glucose, but you'd have some combination of pick for analytics glucose, ketones, lactic acid, some other one where it's maybe 20% lack less accurate all four but you get a picture of everything. That's more of a diagnostic As we look at sensors in the future, that's something we would consider. But that's, you know, that's advanced r&d and something that we would look at. We don't have an intention of going a different direction right now. We believe that the features we have we can migrate to type two without compromising our current patient base. Stacey Simms 21:18 All right, let's talk about some specific type one stuff. And let's talk about following up. And no pun intended there. I apologize on the share and follow issues from late last year, you put out a very sincere apology, you really seem to have taken some steps. I appreciate that. I'm sure it couldn't have been too easy to put that video out, and we appreciate it. Kevin Sayer 21:40 But no, actually, I didn't tell you that that did not bother me at all. We couldn't put it out until we knew the answers. But that's the way we run this company. And that's the way I will always behave. If we do something that doesn't work. You own it. You don't hide and I wanted to do the video of the day with day one and Gemma calming me down, I wanted to write a letter or reduce something I was wasn't happy that we could not go faster. But now we will always behave that way will never behave any differently. Stacey Simms 22:13 I have some questions. Go ahead. Alright. Alright. So my first one is, you've updated the website and I'll put a link in the show notes where people can go to check in just last week, there were a couple of issues that were resolved quickly. But I noticed that what happened to me I'll give you my personal story. I noticed on my follow app for my son that we had lost signal, there was a brief notification, I apologize. I can't remember what it said. But something like you know, server error, but something came up a little teeny red line on the app. I cleared it without even looking at it too closely. And I went on my way because I don't My son is 15 I don't look at the follow up as much as some other parents do. But then on a Facebook group, someone said go and check the Dexcom page because They're updating the situation there is an issue. Great. So we all went. But my first question is, you will have announced, I believe that you're working on push notifications of some kind, because it didn't occur to me and maybe shame on me to go to the website. So can you talk about the timeline for that and what those in app notifications will be? Kevin Sayer 23:19 Sure. But let's go back a step we said and I said in the video, two things we're working on it immediately is a server status page and a product status page on our on our website. So you can go to the Dexcom website, and you can see how the system is functioning. And you can see that clarity is functioning Share and Follow how they're functioning, and we give an update to those in real time, will then implement before in the first half of the year, we're two months into the year almost before the end of June, we will have in app messaging to whereby if there is a share or follow or clarity or whatever issue we can send a message directly to the patient and are the followers servers are down, this is what's going on and it will come in the app won't come through text messaging yet. That'd be something we would do a little bit later. And in all fairness, I don't know that we have everybody's phone numbers to whereby we can push text, but we can't push to the app into the app users. So that'll be here by by mid June. As far as anything going on Recently, there were a couple times when the status page was yellow. And they worked through those quite quickly learning from what's gone on in the past and got that resolved. And we're now establishing the boundaries for what example what yellow server status means, on our webpage. Because when we started this and just adding totally, one of the the apps had yellow and it's happened to two clinics in the whole country. But since it happened to two clinics, we made it yellow, just in case it happened anyplace else on reality. That was the two words had happened and we dealt with it so we're being rather cautious is causing anything that we We will make it yellow over time, we'll put, you know tighter boundaries around that. But we will make it yellow. We'll work through the issues. We've improved our internal communications, I knew something was going on from the minute that thing went yellow, I was getting notifications. And I was I was traveling, so it's going much better. And we'll build a structure up and continue to make it better. That's all I can tell you. So we'll keep improving. Stacey Simms 25:24 And I know that you'll be researching this, but I'll give you some patient feedback real quick is that please don't text me. You don't need my phone number in app notification. Kevin Sayer 25:34 Okay. Yeah, I would rather not understand. balance that with everybody else because you're catching a flight for the airport, what happens? You get a text message. So the expectation since we're on your phone is we have the same infrastructure we just don't Stacey Simms 25:53 do what I don't get a text message from the airline. I get a notification from the app. It shows up on my similarly you get a text from Because you probably, Kevin Sayer 26:01 I guess it depends I Yeah, I know. Anyway, you have to be more like everything else that people experience. Stacey Simms 26:08 Exactly. Okay, so I have a couple of questions. Many of these questions that I've asked have actually already come from my listeners. Of course, we all have a lot of the same questions. But here are a few that people sent in. Rachel, as we're staying here on the follow up. Rachel wanted to know, if you're still working on having the follow app getting same notifications as the primary app, because all of us parents, especially with older kids, now, we never know when the sensors is expiring when the transmitters expiring, is there any work being done to get the follow up to be a little bit more robust for parents work any caregiver? Kevin Sayer 26:43 Yeah, we're continuing to work on the follow up and add add more to it. I think it'll be continual development cycle and will continue to add more. I will tell you from the teenager or the college students share a perspective the last thing they want is their parents. Getting The alerts from their app. I know that firsthand, because I talked to a couple of No, no, no, no. And so we try and balance it all. We will make the the share system more robust as time goes on. Because if we learned anything thing from the server outage, we learned how important share was. It is very important to everybody. Stacey Simms 27:19 Yeah. And all due respect, when you have the first update, when you could make it for 10 followers. You know, not every kid wants everybody their school following them either. I mean, but these have to be parental decisions with good education. So, you know, I think I get what you're saying. But these are all, let's just see, these are wonderful problems technology has created. I try to leave them alone. Alright, so. Okay, the next question came from a few people. And Gosh, I don't know if you can answer this, because this is more anecdotal, but we've been using the G six since May or June of 2018. And it seems to me Just in the last two months, I have seen pictures and heard anecdotal reports of sensors getting stuck at insertion to the point where in my smaller I have a smaller local Facebook group. People are posting the things they have used to whack the sensor because you're supposed to, apparently on Facebook, you whack it with a wooden spoon to get it to release or there might be a button underneath that you can push a pin in. But this is something that we haven't experienced, but that I've seen in the last two months. Are you aware of this? Is this an actual problem that Kevin Sayer 28:33 just so you understand, we monitor every complaint and everything that's coming very closely, we have seen a rise in those instances. Fortunately, it doesn't result in a patient getting bad data or anything bad happen. We just have to replace their sensor. We've identified the root cause of that and we've taken mitigations to correct that and that should come down going forward. We have this this Not this specific issue, but the fact is when we see things rise in the complaint base, we have a group of sustaining engineering group that jumps on these issues and determines where they came from. we've analyzed this, this specifically and we've implemented improvements and you will see that decreasing significantly over the next several months that should go away. Stacey Simms 29:20 Okay, cuz I know the good news is there isn't as readings issue, but the bad news is there's a freakout issue. Kevin Sayer 29:26 There's a freakout issue and let's face it, if that's your last sensor, yeah, that's not fair. And that's not right. So we notice it, we've seen it we've read it and we have we've done everything we can to mitigate that I'm pretty I'm very comfortable we’ll see this come down. Stacey Simms 29:41 Okay, but I'm glad to hear that. Is there actual advice of what to do if it happens? Is there the release underneath? I'm assume whack it with a spoon isn't something that you recommend? Kevin Sayer 29:54 Now we’re in anecdotes and I can’t speak to that. The easiest thing is call us and we’ll get us a new sensor as fast as we can. Stacey Simms 30:02 I gotta ask. I got a couple of questions from listeners who are asking about outside the United States. Obviously our listeners are USA centric, but there are many, many, many in the UK and Australia and Canada. Can you talk a little bit about jif six and G seven, internationally. Kevin Sayer 30:19 So g six is in Canada now. We launched it there in the fourth quarter. We also launched in Canada, any commerce platform reimbursement is not brought in Canada. Many of the patients have to cover the costs on their own. So we have tried to make it easier and Canada is the first place we've ever had an e commerce platform where patients can literally go online and buy their sensitive transmitters have them shipped directly to them without having to deal with this has been a very efficient and a tremendous growth driver up there. A lot more people are getting access to speech him in Canada because of that. That's been a great experience. g six has been available in the UK for quite some time. And again, the UK business is I want to say three reacts when it was two years ago. So we're doing very well there also, reimbursement is coming, but it is sporadic. It isn't everywhere. We spent a lot of time with government authorities pleading our case, the importance of CGM, and we found that educational process great. they've jumped on board and learn a lot Australia, g six is coming. I know it's not broadly rolled out, but it will certainly be a 2020 product there and should do very well in Australia as well. Government reimbursement, for CGM in Australia has gone very well. Here today. It is growing nicely, are all US strategy. We really have three pillars that we're working on, you know, first those countries we're reversing, that is good. We gotta broaden there. We have to increase access in countries where reimbursement is sporadic. And the UK, Spain where I am Italy, some of those places is very sporadic. Some regions it's reimbursed others it's not. Yeah. And then there is where we don't play it all. Yeah, we're very well In Central and South America, or Mexico, where we've got a filing in Japan virtue six, but we're not launched there yet. Stacey Simms 32:08 I'm gonna start this question right here. And it's my fault because I'm running over time. And I want to get one more question in. So I apologize. One more question. Okay, so diabetes mine ran a column recently that was headlined 39 potential new continuous glucose monitors for diabetes. Now a lot of these are pie in the sky. We know many won't come to market, but they went through and listed a bunch of new CGM that are going to be your competition. My last question is about customer service. Talk to us about how you're going to improve, maintain, really try to over serve in terms of customer service, because you know, that in the last year or two as the launch of the G six was a challenge, because of supply, customer service has got to be a challenge too. So my last question is, assure us that it's going to be okay from a customer service standpoint. Kevin Sayer 32:58 Well for us, it will be Well, I will tell you the one thing we've learned this year, more than anything else is scale. It's very difficult. And I just throw some numbers at you. Two years ago, we announced that the JPMorgan conference we had 270,000 active patients. That means we have patients that we know are buying and using sensors. Okay. I announced in an earnings call a week ago that we have 650,000 active using sensor patients. You can imagine the number of sensors we have to produce above and beyond that the number of phone calls we take, we will make customer service priority but scale is a huge challenge here and it is not cheap. We will spend hundreds of millions of dollars getting the g7 factory up and running before you see a sensor. We will invest hundreds of millions of dollars in G six at the same time, getting the factory automated getting the sensors more reliable. At the same time as we looked at the customer experience. There's a lot of things we can do. We have formed an entire customer experience Team at Dexcom over the past 12 months To go back and look at how we interact with people is 43 screens to start up the G six, new from scratch. Why is it 43 screens was because it was 43 screens and we did seven plus or G for whatever, we did the same thing. We're go back and re evaluating all those things to make it easier. I believe also on the customer service side, we do need to get better. But we need to get better a couple of ways. Product reliability is the first thing if we make it so you never have to call them customer service gets that much easier. But inevitably patients are going to, I believe personally that software can alleviate a lot of customer concerns. As we look to the future we look at putting tech support in the app to whereby I'll give you an example if your sensor poops out at eight days, it says Hey, your sensor quantitate days hit yes and we'll send you a new one. We're looking at things like this to make it much easier for our patients to work with us. We We purposely went offshore to set up a customer service center because quite frankly, we could not hire enough resources here to Do so that is going better as well on the distribution channel and make it simpler. We're going to the drugstore with future products and moving g six there. So there's not as much interaction as well. But I can tell you the customer service piece is every bit as hard if not harder than the technology piece. And we take it that seriously and we will over the next several years. Stacey Simms 35:18 Seven, thank you so much for spending some time with me. I apologize to your people because I kept you too long. But I always appreciate talking with you. Kevin Sayer 35:25 Thank you very much. Unknown Speaker 35:32 You're listening to Diabetes Connections with Stacey Simms. Stacey Simms 35:38 I couldn't get to everybody's questions from the Facebook group. I apologize for that. But as you heard, we ran out of time he was doing back to back to back interviews. I don't know who was next in the queue. I'm sorry. I did make him a couple of minutes late. But just a couple of quick thoughts on on my talk with Kevin they're listening back and I do listen back to almost every interview before we air it. I sounded so offended about the text messages. Do not like that I don't know about you. I want text messages to be from my family, friends and emergencies. I'll take text messages from school, and maybe some alerts. But I want my apps to notify me through the app. And I want to be able to opt in and out of that. I know a lot of people disagree. You know, if you listen to the show for a long time, we don't use share and follow like a lot of parents, I have never let any school personnel follow my kid. We do not see the need, but that is us. So you know, I understand Dexcom has to do its market research and make everybody as happy as they can. The other thing that occurred to me is that when he talked about going direct to watch, and not announcing it, right, waiting till all the transmitters are out there and then announcing it. My first thought was and so many of us who listen are part of the DIY community. I don't know what you do or how you do it. But the first thing that occurred to me was it's going to take five minutes for these DIY folks to figure out that different transmitters are out there. So I'm relying on you to let us all know because I have a feeling As soon as they start shipping whenever that is and he didn't indicate when, you know, I mean really how long it's going to take people to notice that it's direct to watch because I know there are people out there who every time they get a new transmitter their check up next, tell me something good with one of my favorite past guests, Sierra Santa said, we will tell you what she is up to now she was in the Miss America Pageant just a few years back. But first, as I mentioned, Diabetes Connections is brought to you by Dexcom. And here's what I have to say about Basal IQ. Now, you know, we switched over to control IQ. But the first iteration of this the first software was basal IQ, the Dexcom g six tandem pumps software program. And when we got it, we started doing less work for better results. Should I say that again? less work, better results with diabetes. Vinny always liked seeing his CGM on his pump. But you know, before this change that was really just kind of a cool feature. I mean, he really didn't pull this pump out just to check a CGM. He looked at his phone, but there was some serious sauce and the basal IQ that kept many more steady. His timing range increased significantly when we started on basal IQ. And his agency, you know, we don't share specific numbers, but not only did it come down, it stayed down. It has been the same, really for more than a year. Now, as I think about it, it's just been great. Of course, individual results may vary. To learn more, just go to diabetes, connections dot com and click on the Dexcom logo. Right, tell me something good. Really My favorite part of every show. Send me your good news stories for those of you not familiar with Sierra Sandison, and I think most of you probably are, she was in the Miss America Pageant in 2014. I had to look that up because I can't believe it's it's been that long already. But she went on stage first in the Miss Idaho pageant in July of 2014, with her insulin pump, clipped to her bikini bottom, you know, when they had the swimwear competition, and then she created the hashtag Show me your pump, which went viral. And I didn't know this till recently, it was NPR as most popular online story that year. Well, then she walked the runway again at the Miss America Pageant with the insulin pump again on her bathing suit. And you know, we all went bananas. Well, since then Sierra has gone back to school. She's at Boise State University. She's at the College of Engineering there. And last week, she won her team. She's on a team for this, she won invent for the planet. This is a competition where engineering teams come up with inventions and solutions to make the world's a better place. So they only had 48 hours to do this. It's a pretty wild competition. I will link up more information about it so you can see exactly what happened there. And I'll put some pictures in the Facebook group too. But it's a team looks like a team of five people and Sierra posted. We slaved away at the 48 hour event for the planet competition this weekend and it paid off. We had so much fun and so little sleep, but then it gets even better. Couple of days later, she was recognized by the Idaho Society of Professional Engineers. As the number one student in her class of mechanical engineers, she writes, I am so humbled and still in shock this week seems too good to be true. Thank you to everyone who helped me get to where I am today. I hope to make you proud and keep wearing pink while doing it. Every time I talked to Sierra, you know, it's easy to forget that she is brilliant, right? We look at the bathing suit, which is how most of us first saw her and we're distracted by that. I mean, I'll be honest with you. When I look at Sierra, I'm always thinking about how bad my hair looks because she always looks gorgeous. Her hair looks great. Her makeup looks great. I have joked with her about setting her up to do a clinic for moms at like a friends for life conference that because we all need to walk around with a ton of makeup. I don't know she doesn't all the time either. Just because it's fun, right? It would be kind of fun to learn how to do pageant makeup like that. I'm getting way off topic, but it's So easy to forget when a woman is beautiful that she is also brilliant. And I think that that is so important to keep in mind. And I'm so thrilled that she is so far forward in sharing all of these accomplishments and not compromising what she enjoys, which seems to be engineering and wearing pink and looking fabulous. So Sierra, thanks for continuing to include us in your journey. I cannot wait to see what you do next. Just let us know when you're taking over the world who would appreciate a little bit of a heads up if you have a Tell me something good. Please send it my way. You can email it to me Stacy at Diabetes Connections. com reach out through social media the Facebook group is a really easy way to do it every once in a while I'll post and ask and other Facebook groups but please seek me out I would love to hear from you. Help me spread the Good News in our community. As this episode goes live, it is the last week of February I don't know January dragged by February flew by I'm afraid to The page to March that we have a lot going on. I have three appearances for the book tour. I'm going to be in Wilmington, North Carolina, Winston Salem, North Carolina, and then over to Indianapolis, for the friends for life conference there. I am getting requests for the fall already definitely booking things in September. I think I have something in December already. So if you'd like me to come speak to your group, reach out. I'm trying not to do too many of these a month. I'm trying not to travel every single weekend because I still do have Benny at home even though my daughter's in college. So it's a lot of balancing juggling going on, but I'm loving every minute of it. Our next episode is coming up on Thursday, I'm going to be talking about a little bit of a Twitter kerfuffle. I don't know if any of you saw this if you're on Twitter, but there was a bit of a disagreement started by an eye doctor, a disagreement between how many doctors see their duty to give patients a wake up call and how people with diabetes actually view that wake up call and a real big gulf between these two groups on this One Twitter chat, unfortunately. So I want to share that with you and maybe how we can get our doctors to listen a little bit more. Alright. Alright, thanks as always to my editor john Kenneth from audio editing solutions. Thank you so much for listening. Joining me, please spread the word about this show. Word of mouth is the best way to grow a show like this. We can get more good information into the hands of people who really need it. So post it on your Facebook page, tell a friend who's touched by diabetes about it. I'd really appreciate it. I'm Stacey Simms. I'll see you back here on Thursday. Unknown Speaker 43:37 Diabetes Connections is a production of Stacey Simms media. All rights reserved. All rounds avenged Transcribed by https://otter.ai

Diabetes Austria
20 – ATTD 2020 - Interview mit Frau Prof. Dr. Yvonne Winhofer-Stöckl

Diabetes Austria

Play Episode Listen Later Feb 21, 2020 6:36


Assoc.Prof.PD Dr.Yvonne Winhofer-Stöckl ist Fachärztin für Innere Medizin/Endokrinologie und Stoffwechsel, Oberärztin am AKH Wien und Leiterin der Diabetes- und Fettstoffwechselambulanz

Diabetes Austria
19 – ATTD 2020 - Søren Smed Östergaard über den NovoPen 6

Diabetes Austria

Play Episode Listen Later Feb 21, 2020 8:26


Der NovoPen 6 mit NFC-Technologie (Near Field Communication) kommt 2020 auch in Österreich auf den Markt

Diabetes Austria
18 – ATTD 2020 - Aurelian Briner über die von ihm entwickelte Food-App SNAQ

Diabetes Austria

Play Episode Listen Later Feb 21, 2020 3:49


SNAQ hilft individuelle Ernährungs- oder Fitness-Ziele zu erreichen

Diabetes Austria
21 – ATTD 2020 – Interview mit Dr. Michael Müller-Korbsch

Diabetes Austria

Play Episode Listen Later Feb 21, 2020 7:29


Typ 1-Diabetiker und Pionier bei Telemedizin

Diabetes Austria
17 - ATTD 2020 – Interview mit Dr. Matthias Koehler

Diabetes Austria

Play Episode Listen Later Feb 20, 2020 5:17


Senior Solution Development Manager bei Roche

Diabetes Austria
16 - Eröffnung ATTD 2020 Madrid

Diabetes Austria

Play Episode Listen Later Feb 20, 2020 5:12


The 13th International Conference on Advanced Technologies & Treatments for Diabetes

Aligned to the Divine Podcast
ATTD 5: AVOID THE BURNOUT- TAKE THE BREAK! Allowing yourself to REST

Aligned to the Divine Podcast

Play Episode Listen Later Jan 27, 2020 36:16


-The New Moon in Aquarius just happened and I will be praying that all the intensions you set out will manifest beautifully! I felt really called to speak on this topic today, I cover how to see the signs of a burnout, why we have burnouts and how we can use it to our advantages, for our soul's growth, and for our own personal development! Lets set ourselves up to manifest all we have been working towards! Connect with me @alignedtothedivine on IG!

Aligned to the Divine Podcast
ATTD 4: How do you become a morning person? Is the gut really the second brain? And how we can save up to conquer goals in 2020!

Aligned to the Divine Podcast

Play Episode Listen Later Jan 20, 2020 19:08


-Happy Aquarius SZN! Happy 2020! Today, I am sharing some tips that I hope elevate your life as it has mine ! 2020 all my spirt fam eating at the table good! Lets set ourselves up to manifest all we have been working towards! Connect with me @alignedtothedivine on IG! Do check out @spiritdaughter to add some high vibe content onto your feed!

Aligned to the Divine Podcast
ATTD 3: How to ring in 2020 like a BOSS!

Aligned to the Divine Podcast

Play Episode Listen Later Dec 29, 2019 21:25


-Happy Capricorn SZN! Here are some of the things that I will be taking into the new year with me :) and I hope you do too! Lets set ourselves up to manifest all we have been working towards! Connect with me @alignedtothedivine on IG! Do check out Leeor Alexandra on youtube! A great start if you are looking to explore your spirituality!

Aligned to the Divine Podcast
ATTD 2: SELF SABOTAGER: Why You Can’t UpGrade

Aligned to the Divine Podcast

Play Episode Listen Later Dec 8, 2019 34:38


-This is Part 1 of a self-sabotage list I made that I noticed I was doing. Let’s go into 2020 with a deeper understanding of ourselves, our triggers, and ways to combat it. I hope this shines some light on your situation and I sincerely pray that it helps you elevate! Let me know your thoughts @alignedtothedivine on IG! Don’t forget to share it with friends and family! A huge shoutout to @justantionetta for posting some dope content! Be sure to give her a follow! And let her know Aligned To The Divine Sent ya over! Ep 2 Affirmations (feel free to use these everyday for 21 days to elevate your vibe and transform your life):

Stein Monogastric Nutrition Lab Podcast
Effects of copper hydroxychloride and increasing concentrations of dietary fat on growth performance, total tract endogenous loss of fat, and ATTD of fat by growing pigs

Stein Monogastric Nutrition Lab Podcast

Play Episode Listen Later Jun 28, 2019 11:17


Charmaine Espinosa, a Ph. D. student in the Stein lab, presents the findings of two studies of the effects of copper supplementation on growing pigs. Although it is known that high levels of dietary copper can promote growth in pigs, the mechanism by which this occurs is not fully understood. In her research, Espinosa examined growth performance, endogenous loss of fat, and ATTD of fat in pigs fed diets with and without supplemental copper. Adapted from a presentation at the 2019 ASAS Midwestern Section meeting, Omaha, NE, March 11-13.

Diabetes by the Numbers
Diabetes By The Numbers

Diabetes by the Numbers

Play Episode Listen Later Feb 11, 2019 22:40


One of the surprising things I've found out about myself while interviewing people for Diabetes By The Numbers is that I'm one of the worst pronouncers of names I've ever met. That's horrible, especially when I have a guest as special as Renza Scibilia. Renza is a diabetes superhero worldwide, with her blog, her work for a large diabetes organization in Australia, and her presence at the forefront of the most important issues facing all of us. After Renza gets me straightened out on the correct pronunciation of her last name, we talk about the upcoming ATTD conference in Berlin, the importance of #LanguageMatters, and how critical the Spare a Rose campaign is. Which is timely, because this episode of Diabetes By The Numbers is part of Diabetes Podcast Week, February 10 through 16. All of the podcasters and video bloggers are throwing their efforts this week behind the Spare a Rose, Save a Child campaign through the International Diabetes Federation's Life for a Child program. As I've mentioned before, the cost of one rose (about $5 USD) saves the life of a child for one month. The cost of a dozen roses gains a child in another part of the world an entire year to play, go to school, and be with their families. Who doesn’t love that? There are children all over the world who are depending on us. So please, take time right now. Go to LFACInternational.org/SpareaRose and make your life-sustaining donation.  I hope you enjoy my conversation with Renza! Reference Material - Click below for more information on this topic Renza Scibilia is a gifted writer, and you can read her at: Diabetogenic.wordpress.com Be part of the Spare a Rose, Save a Child campaign this year by making your donation at: LFACInternational.org/SpareARose

australia child berlin numbers diabetes usd spare attd renza scibilia scibilia sparearose diabetes podcast week
Diabetes Connections with Stacey Simms Type 1 Diabetes
What's Next for Tandem? T:slim & Beyond

Diabetes Connections with Stacey Simms Type 1 Diabetes

Play Episode Listen Later Feb 5, 2018 55:47


Find out the latest from Tandem, makers of the T:slim insulin pump. Spokesperson Molly McElwee Malloy shares how close they are to a hybrid closed loop, which they're calling Control IQ, and other products.  Malloy. diagnosed with type 1 as a young adult, was  in one of the first artificial pancreas trials back in 2006 (not with Tandem). Also a nurse & a CDE, she talks about her personal story and why she's excited about this technology.  In our Know Better Segment.. two potential and very small insulin delivery devices are getting big grants. And.. it’s almost time for Diabetes Podcast Week!   ------ 1:30 Stacey welcome / explains a bit about the Tandem interview and the ATTD conference.  4:45 Interview with Tandem's Molly McElwee Malloy 49:15 Know Better: JDRF grants for two potential insulin delivery/CGM systems 52:30 Diabetes Podcast Week info ----- Sign up for our newsletter here Get the App and listen to Diabetes Connections wherever you go! Click here for iPhone      Click here for Android     

Stein Monogastric Nutrition Lab Podcast
Effects of high protein canola meal on digestibility of phosphorus and growth performance in pigs

Stein Monogastric Nutrition Lab Podcast

Play Episode Listen Later Sep 27, 2016 14:40


Yue She, former visiting scholar in the Stein lab, discussed the results of two studies investigating the effects of feeding high protein canola meal to pigs. The objective of the first study was to determine the ATTD and STTD of phosphorus in high protein canola meal fed to growing pigs. The second study was conducted to determine the optimum inclusion rate of high protein and conventional canola meal in diets fed to weanling pigs. Adapted from a presentation at the 2016 ASAS Midwestern Section meeting, Des Moines, IA, March 14-16.

Stein Monogastric Nutrition Lab Podcast
Effect of fat sources on ATTD of minerals

Stein Monogastric Nutrition Lab Podcast

Play Episode Listen Later May 23, 2016 10:29


Dr. Laura Merriman, a recent Ph. D. reciepient from the Stein Monogastric Nutrition Laboratory, discusses her research into the effects of saturated and unsaturated fat on mineral digestibility in growing pigs. Adapted from a presentation at the 2016 ASAS Midwestern Section meeting, Des Moines, IA, March 14-16.

Stein Monogastric Nutrition Lab Podcast
Effect of phytase on ATTD and STTD of Ca in feed ingredients of animal origin fed to growing pigs

Stein Monogastric Nutrition Lab Podcast

Play Episode Listen Later Apr 13, 2016 14:10


Laura Merriman, a Ph. D.candidate in the Stein Monogastric Nutrition Laboratory, discusses her research into the effects of adding microbial phytase on the digestibility of calcium in diets containing meat and bone meal, meat meal, poultry byproduct meal, and poultry meal. Adapted from a presentation at the 2016 ASAS Midwestern Section meeting, Des Moines, IA, March 14-16.

Stein Monogastric Nutrition Lab Podcast
Effect of novel carbohydrates on AID and ATTD of GE and nutrients in semi-purified diets fed to pigs

Stein Monogastric Nutrition Lab Podcast

Play Episode Listen Later Sep 22, 2011 14:53


Dr. Sarah Cervantes-Pahm discusses recent research into the digestibility of energy and nutrients in four novel carbohyrates: resistant starch 60, resistant starch 75, soluble corn fiber 70, and pullulan.